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INTRODUCTION 
 1 
INTRODUCTION 
 
 Preterm birth, defined as birth at less than 37 + 0 weeks of gestation, is 
the most important determinant of adverse infant outcome in terms of both 
survival and quality of life. It contributes to significant neonatal morbidity and 
mortality. 
 Children who are born prematurely have a higher risk of cerebral palsy, 
sensory deficits, learning disabilities and respiratory illness compared to those 
born at term. The social and emotional cost of the above consequences is 
immeasurable (Wang, 2004). 
 However, preterm labour must ideally be prevented. Pharmacological 
therapy with a variety of drugs of different categories has been the primary 
method of treating acute preterm labour and delaying preterm delivery. 
 Our challenge remains to identify interventions that prevent preterm 
birth and reduce the morbidity and mortality and expense associated with 
prematurity. 
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AIM OF THE STUDY 
 
 To administer corticosteroid therapy to improve fetal lung maturity. 
 To compare the safety and efficacy of intravenous MgSO4 and oral 
nifedipine in acute tocolysis. 
 To record the effects of the above two drugs on the mother and the fetus. 
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REVIEW OF LITERATURE AND DRUG 
PHARMACOKINETICS 
 
DEFINITION 
 Preterm labour is defined as the occurrence of regular, painful, frequent 
uterine contractions associated with progressive cervical effacement and 
dilatation before 37 completed weeks of gestation from the first day of last 
menstrual period (WHO, 1992). 
 The period of viability varies in different countries from 20 to 28 weeks 
depending on the facilities available for newborn care and the likelihood of 
survival. In India, for legal purposes viability is defined as any gestation carried 
beyond 28 weeks (196 days). On a practical note, every centre has to recognise 
its lower limit for salvaging babies in the event of such a delivery. 
 American Academy of Pediatrics and American College of 
Obstetricians and Gynaecologists considered preterm labour to be established 
if regular uterine contractions can be documented atleast 4 in 20 minutes or 8 in 
60 minutes, with cervical dilatation greater than 1 cm and cervical effacement 
of 80% or greater (Cunningham et al., 2010). 
 
INCIDENCE 
 Spontaneous preterm birth before 37 weeks gestation occurs in 7 - 11% 
of pregnancies and before 34 weeks gestation in 3 - 7% of pregnancies 
(Maternal and Child Health Consortium. 6th Annual Report, 1999). 
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Preterm delivery, particularly that before 34 weeks gestation, accounts for 
three-quarters of neonatal mortality and one-half of long term neurological 
impairment in children, including developmental delay (Paneth NS, 1995; 
Stewart AL , Amess PN et al., 1999).  The incidence in India being 10-14% 
(FOGSI). In Mahatma Gandhi Memorial Government Hospital,  Trichy 
 the incidence is 13%. 
 
IMPACT OF PRETERM BIRTH 
 A preterm infant is defined as one who is born at less than 259 days (37 
completed weeks) of pregnancy (WHO, 1977). 
Maternal mortality and morbidity as a consequence of preterm birth are 
rare. The most common maternal complication is postpartum endometritis 
which responds rapidly to administration of antibiotics (Fernando Arias, 3rd 
Edn.) 
 The birth and subsequent hospitalisation of a very premature infant 
evokes considerable psychological distress in mothers. 
 
Risks of preterm infant 
 Neonatal survival for preterm infants is directly related to their 
gestational ages and birth weights (Fernando Arias, 3rd Edn.). Problems of 
preterm birth are related to difficulty in extrauterine adaptation due to 
immaturity of organ systems. 
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Short term problems (Manual of Neonatal Care, 2011) 
(1) Respiratory 
 Perinatal depression 
 Respiratory distress syndrome 
 Apnoea due to immaturity 
(2) Neurologic 
 Intraventricular haemorrhage (germinal matrix haemorrhage) 
 Periventricular leukomalacia 
(3) Cardiovascular 
 Hypotension 
 Patent ductus arteriosus. 
(4) Haematologic 
 Anemia 
 Hyperbilirubinemia 
(5) Nutritional Problems 
 Growth failure 
(6) Gastrointestinal 
 Necrotising enterocolitis 
 Feeding intolerance 
(7) Metabolic 
 Hypoglycemia 
 Hypocalcemia 
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(8) Renal 
 Water and electrolyte imbalance 
 Acid - base disturbances 
(8) Temperature Regulation 
 Hypothermia 
(9) Immunologic 
 Sepsis 
(10) Ophthalmologic 
 Retinopathy of prematurity 
 
Long term problems (Manual of Neonatal Care, 2011) 
(1) Chronic Lung Disease 
 Bronchopulmonary dysplasia 
 Wilson Mikity Disease 
 Chronic pulmonary insufficiency of prematurity. 
(2) Nutritional 
 Failure to thrive 
(3) Cardiovascular 
 Pulmonary hypertension 
 Hypertension  in adulthood 
(4) Immunologic 
 Recurrent respiratory infections 
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(5) Central Nervous System 
 Cerebral palsy 
 Developmental delay 
 Sensorineural deafness 
 Language disorder 
 Learning disabilities 
(6) Ophthalmologic 
 Retinal detachment 
 Myopia 
 Strabismus 
(7) Metabolic 
 Impaired glucose regulation 
 Insulin resistance 
Preterm birth is a significant cost factor in healthcare, not considering 
the expenses of long-term care for individuals with disabilities (who require 
special needs, education, mobility aids and additional healthcare) due to 
preterm birth. It has been calculated that prematurity is responsible for 35% of 
all healthcare spending (Lewit E, Baker L et al., 1995). The costs increase 
exponentially with decreasing gestational age and weight. There are also major 
implications in terms of psychological and social impact of disability on the 
individuals and their careers. 
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ETIOLOGY 
 A wide variety of etiological factors have been implicated in the 
causation of preterm labour, although in large majority of patients no definite 
cause can be found. 
 Nearly 50-60% of preterm births occur following spontaneous labour, 
30% due to preterm premature rupture of membranes and the rest are iatrogenic 
terminations for maternal or fetal benefit (Goldenberg RL, 2002; Leitich H, 
2005). 
 
(1) Infections 
 Goldenberg and Colleagues (2008) have reviewed the role of infection 
in preterm birth. 
(a) Uterine 
 Infection is the most clearly recognised and more widely studied cause 
of preterm birth. Infection is responsible for about 50% of all cases of 
spontaneous preterm birth (Klein LL, Gibbs RS, 2005). The most rigorous 
criteria for diagnosis of infection are positive cultures or demonstration of 
bacterial “fingerprints” by Polymerase Chain Reaction (PCR) in the amniotic 
fluid. 
 The most accepted mechanism of infection causing preterm birth is 
ascending infection. Bacteria may also gain access to the amniotic cavity 
through haematogenous spread or by introduction at the time of invasive 
procedures. 
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 Studies demonstrate association between colonisation of genital tract 
with specific microorganisms and preterm labour. These include niesseria 
gonorrhoea, group B streptococci, chlamydia trachomatis (Alger et al., 1988), 
mycoplasma hominis and ureaplasma urealyticum (Lamont et al., 1987), 
gardnerella vaginalis, bacteroides species and haemophilus species (McDonald 
et al., 1991, Kurki et al., 1992). Asymptomatic bacterial vaginosis and 
trichomonas vaginalis confers a modest risk of spontaneous preterm birth. 
 The relative risk of preterm labour is doubled if the mother has bacterial 
vaginosis (Goldenberg RL, Iams JD, Mercer BM, et al.)  Women with 
bacterial vaginosis and susceptible TNF-α genotype had a 9 fold increased 
incidence of preterm labour. Bacterial vaginosis infection in early pregnancy 
may be at a greater risk factor than in late second trimester and early third 
trimester of pregnancy (Hay PE, Lamont RF et al.). Bacterial vaginosis 
(Gravett et al.) has association with low birth weight. 
 
(b) Extrauterine 
 Approximately 5-10% of patients in preterm labour have infection 
outside the uterus, most commonly in the urinary tract (Romeo et al., 1988). 
 Systemic infections like pyelonephritis, pneumonia, acute appendicitis 
often lead to increased uterine activity and preterm labour (Am J Obstet 
Gynecol., 2006). Periodontal disease is associated with preterm labour 
(Xiong X., 2006). 
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(2) Placental 
 Abnormal placentation 
 Anatomical abnormalities 
 Placenta previa 
 Abruptio placentae 
 
(3) Uterine 
 Congenital abnormalities (1-3%) 
 Anatomic or physiologic abnormalities of uterine cervix (Nohr et 
al., 2007). 
 Uterine overdistension. 
 
(4) Genetic 
 The recurrent, familial and racial nature of preterm birth has led to the 
suggestion that genetics may play a causal role (Anum, 2009;  Lie, 2006  and 
all their co-workers). 
 Single gene polymorphisms of cytokines in both mother and fetus may 
be responsible.  Polymorphism involving tumour necrosis factor -α 308 (TNF-
α 308), interleukin-1 beta (1L-1β) and interleukin-6 have been most consistently 
associated with spontaneous preterm labour and preterm birth (Varner MW, 
Esplin MS, 2005). 
 
(5) Vaginal bleeding in early pregnancy is associated with increased adverse 
outcomes later (Weiss and Associates, 2004). Threatened first or early second 
trimester miscarriage doubles the risk of subsequent preterm labour. 
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(6) Fetal 
Dolan and colleagues (2007) found that birth defects were associated 
with preterm labour. 
 Pregnancies complicated by fetal malformations, in particular multiple 
anomalies, renal anomalies and anterior abdominal wall defects, deliver 
preterm more often than expected. 
 
(7) Preterm labour of unknown origin (20-30%) 
 
(8) Iatrogenic 
 Developments in the field of antenatal diagnosis, maternal fetal 
medicine and neonatology have lead to increased early interventions by 
obstetricians. Conditions which threaten maternal and fetal well being (which 
account for one third of cases) are at risk of being delivered before term.  
 This number is on the rise with the availability of advanced fetal 
surveillance and imaging technology such as cardiotocograph and high end 
ultrasound machines. The practice of ‘defensive medicine’ as a result of 
increase in litigation has only increased the burden (Arulkumaran, 3rd Edn.). 
 Increase in the number of multiple pregnancies, particularly higher order 
pregnancies, resulting from the use of fertility drugs and assisted reproduction 
is also one of the major reasons for increase in incidence of preterm birth. 
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PATHOPHYSIOLOGY 
 The molecular basis of initiation of labour is unclear but a number of 
theories have been proposed. 
 Maternal stress is a well recognised cause of activation of the 
mechanism of normal parturition, regulated by hypothalamic secretion of 
corticotrophin - releasing hormone or CRH (Hobel et al., 1999). 
 The fetal pituitary adrenal axis needs to be intact (Gonik B et al.). As 
parturition nears, the fetal adrenal axis becomes more sensitive to ACTH and 
there is an increased production of cortisol. This stimulates  17- hydroxylase in 
the trophoblast resulting is decreased progesterone secretion. The reversal of 
the estrogen-progesterone ratio leads to increased prostaglandin formation and 
initiation of labour. 
 Cytokines are released when there is inflammatory response to infection 
and intrauterine bleeding (Cox & Colleagues, 1993). These inturn stimulate  
arachidonic acid and prostaglandin production. 
 
Labour as an Inflammatory Process 
Cytokines Action Effect 
IL-6, IL-8, IL-1, TNF-α Degradation of collagen fibres Cervical ripening 
IL-1 & TNF-α Induce matrix 
metalloproteinases Membrane rupture 
IL-1, IL-2, IL-6, TNF-α Increase PGE2, PGF2α Uterine contractions 
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Differential production of PGE2 and PGF2α by the three enzymes – 
phospholipases, PGH2 synthase, 15-hydroxy prostaglandin dehydrogenase may 
be a key in the balance between uterine quiescence and activity. 
 Whatever the mechanism to initiate labour, three physiological 
processes have to occur, namely, softening and dilatation of cervix, uterine 
myometrial contractions and weakening and rupture of the membranes. 
 
EPIDEMIOLOGY 
(1) Racial and Ethnic Disparity 
 Black women have twice the risk of preterm delivery compared to 
whites (Varner MW, Esplin MS, 2005). This may be explained by socioeconomic 
status, medical disorders and genetic predisposition. 
 The magnitude of risk is greatest for extremely preterm deliveries 
(Schoendorf et al., 1992). 
 
(2) Age 
 There is an increased risk of preterm delivery in women under 20 years 
of age (Lumley, 1993) and in women over 35 years of age. 
 
(3) Parity 
 Primiparity is associated with a higher rate of preterm delivery 
independent of age (Bakketeig and Hoffman). 
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(4) Socioeconomic Status  
 The universal effect of low socioeconomic status on health appears to 
directly affect the incidence of preterm labour (Moutquin, 2003). 
 
(5) Weight 
 Poor nutrition, low maternal prepregnancy weight (BMI < 20 kg / m2) 
and poor weight gain (less than 0.24 kg / wk) are associated with an increased 
risk of preterm labour (Wen et al., Barros et al., 1992). Prenatal weight gain is 
specifically associated with preterm birth (Hickey & Colleagues, 1995). 
 
(6) Stature 
 Short statured mothers have more tendency to produce preterm babies. 
 
(7) Addiction 
 Smoking was found to be a significant independent factor associated 
with increased risk of preterm labour at 27-32 weeks (Burguet A, Kaminshi M, 
2004). 
 Cocaine use increases the rate of preterm delivery, in part a consequence 
of a higher risk of abruptio placentae (Volpe, 1992). 
 An increased risk as a consequence of alcohol consumption remains 
unproven. 
 More recent data confirm an excess of preterm births in opiate users 
(Boer et al., 1993, Walkinshaw et al., 1993). 
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(8) Work During Pregnancy 
 Occupational factors such as prolonged walking or standing, strenuous 
working conditions and long weekly work hours (> 42 hrs / week or > 6 hrs / 
day) had a greater risk of preterm labour (Casanueva, 2005, Giel Chinsky, 
2002). 
 
PREDISPOSING FACTORS 
(1) Psychosocial Factors 
Recent studies have shown association between preterm birth and anxiety, 
stress and depression, negative life events, perception of racial discrimination 
and domestic violence (Goffinet F, 2005; Hogne CJ; Bremner JD, 2005). 
 
(2) Coitus 
 Coitus during early pregnancy was not found to be associated, but 
increasing number of sexual partners increased the risk of recurrent preterm 
delivery (Yost NP, Owen J, 2006). 
 
(3) Past Obstetric History 
(a) Previous preterm birth 
 Previous preterm birth is the single best predictor of preterm delivery 
(Wen et al., 1990). The recurrence risk ranges from 17-40% depending on the 
number of previous preterm deliveries (Carr-Hill et al., 1985). Risk increases 
with the number of preterm births and decreases with the number of term 
deliveries. 
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(b) Previous spontaneous miscarriage 
 There is no association with history of one or two first trimester 
abortions, but three or more abortions increase the risk of preterm labour. 
 Previous second trimester spontaneous miscarriage carries an increased 
risk of subsequent preterm labour (Keirse et al., 1978). 
(c) Uterine abnormalities 
 The most clinically significant of these conditions are the septate and 
bicornuate uterus with incidence of preterm birth varying between 16-20 
weeks. 
(d) Previous pregnancy bleeding 
 Women with a past history of antepartum bleeding especially abruptio 
placentae, are at increasing risk of recurrence (Crenshaw et al., 1973) and 
therefore are at increased risk of repeated preterm delivery. 
(e) Cervical insufficiency (or incompetence) 
 Cervical insufficiency is a known risk factor for preterm labour and 
contributes to 10-25% of second trimester losses (Vidaeff AC et al., 2006). 
 
(4) Current Pregnancy Complications 
 Many pregnancy complications are associated with preterm birth. 
 Multiple pregnancy 
 Preexisting medical illness 
 Asymptomatic bacteriuria 
 Preeclampsia 
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 Antepartum haemorrhage 
 Polyhydramnios 
 Fetal malformation 
 Assisted conception pregnancy 
 
(5)  Interval Between Pregnancies 
 It was shown that intervals shorter than 18 months and longer than 59 
months were associated with preterm birth (Conde-Agudelo, 2006). 
 
(6) Fetal Gender 
 The main fetal factor influencing the rate of preterm delivery is fetal sex, 
with the preponderance of males delivering preterm. 
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RISK FACTOR SCORING  
 A risk scoring system devised by Papiernik and modified by Creasy 
and Govit (1986) has been tested in several regions. Women with a modified 
risk assessment score of 10 or higher are considered to be at high risk for 
spontaneous preterm labour. 
 Scoring system is based on epidemiological risk factors. Past 
reproductive history plays a major role, with a history of previous preterm 
births, second trimester miscarriages and cone biopsy all scoring highly 
(Creasy et al., 1980; Holbrook et al., 1989). Overall performance of risk 
scoring, though easily applied, has been poor. Pooled results give a sensitivity 
of only 40%, positive predictive value of 20-30% and false positive rate of 
almost 80% (McLean et al., 1993). Such results fail to identify most women at 
risk and falsely label many normal pregnancies as at risk, exposing them to 
potential interventions and is of limited clinical use. 
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PAPIERNIK RISK SCORING SYSTEM 
 Screening for risk of preterm labour, other than historical risk factors, is 
not beneficial in the general obstetrical population (ACOG, 2008). 
Points Socioeconomic Factors 
Previous 
Medical History Daily Habits 
Aspects of 
Current 
Pregnancy 
1 
Two children at 
home, low socio-
economic status 
One abortion, 
less than 1 year 
since last birth 
Works outside Unusual fatigue 
2 
Maternal age < 20 
years or > 40 
years, single 
parent 
Two abortions 
Smokes more than 
10 cigarettes per 
day, more than 3 
flights of stairs 
without elevator 
Gain of < 5 kg 
by 32 weeks 
3 
Very low socio-
economic status, 
height < 150 cm, 
weight < 45 kg 
Three abortions 
Heavy or stressful 
work that is long 
and tiring, extensive 
travelling, long 
daily commuting 
Breech at 32 
weeks, weight 
loss, head 
engaged at 32 
weeks, febrile 
illness 
4 Maternal age < 18 years Pyelonephritis  
Bleeding after 
12 weeks, short 
cervix, opened 
internal os, 
uterine 
irritability 
5  
Uterine anomaly, 
second trimester 
abortion, DES 
exposure, cone 
biopsy 
 
Placenta previa, 
hydramnios 
10  
Preterm delivery, 
repeated second 
trimester 
abortion 
 
Twins, 
abdominal 
surgical 
procedure 
Table adapted from Creasy et al., 1980. 
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SCREENING METHODS FOR PREVENTION OF PRETERM LABOUR 
Prediction of preterm birth is an important strategy in reducing neonatal 
morbidity and mortality. Various means have been used to identify the women 
at risk. A good primary marker should be applicable to both asymptomatic as 
well as symptomatic women. The two most promising markers currently 
available are fetal fibronectin levels and ultrasound assessment of cervical 
length. 
 
(1) Cervical Changes 
(a) Cervical Dilatation 
 It has been widely assumed that premature effacement or dilatation of 
cervix is related to an increased risk of preterm delivery. Approximately 25% 
of women whose cervices are dilated 2 or 3 cm deliver prior to 34 weeks. 
Positive predictive value of cervical changes range from 4 to 30% (Leveno et 
al., 1986; Mortensen et al., 1987). 
(b) Cervical Length – The short cervix 
 Changes in the anatomy of cervix - endocervical shortening , dilatation 
and herniation of membranes (funneling) are considered as changes along a 
continuum in the early stages of preterm labour. This cervical remodeling can 
be viewed on ultrasound imaging. Transvaginal ultrasound is currently 
recommended as the most reliable method which is reproducible as opposed to 
transabdominal and translabial methods (Berghella et al., 2005). Studies have 
shown that the risk of preterm labour is inversely proportional to the cervical 
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length at 24 to 28 weeks. Serial measurement appears to be superior to a single 
measurement in assessing the risk of preterm delivery. 
 Transvaginal cervical measurement identifies about 1% of the 
population who are at high risk for preterm delivery. A cervical length greater 
than 25 mm would be considered normal. A shortened cervix in association 
with ‘funneling’ has been shown to be an indicator of greater risk of preterm 
delivery (Rust et al., 2005).  
 Berghella et al showed that funneling or dilatation of the internal 
cervical os > 5 mm is associated with a positive predictive value of 33 – 40 % 
for preterm labour versus 11.3 % for a short cervix. 
 
(2) Cervicovaginal Fetal Fibronectin  
 Fetal fibronectin is a basement membrane protein produced by 
trophoblasts. It acts as a ‘glue’ holding the placental membrane and the decidua 
together.  
 Several metaanalysis have confirmed the value of fetal fibronectin in the 
prediction of preterm birth in symptomatic and asymptomatic women (Faron 
et al., 1998; Honest et al., 2002). 
Swabs can be taken from ectocervix or posterior vaginal fornix and an 
ELISA with an FDC-6 monoclonal antibody is used to detect fetal fibronectin. 
Levels > 50 ng / ml is usually considered positive. A negative fetal fibronectin 
indicates that delivery will not occur in the next 2 or 3 weeks, while a positive 
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result will increase markedly the possibilities of preterm labour and delivery 
before 34 weeks. 
 It has a high false positive rate as a result of contamination of sample 
with maternal blood or semen, speculum or digital pelvic examination, 
endovaginal ultrasound examination and in women with cerclage, rupture of 
membranes. Serial sampling improves positive predictive accuracy but with a 
lower specificity. 
The high negative predictive value of fetal fibronectin can be used to 
influence management. 
 The usefulness of fetal fibronectin testing along with transvaginal 
ultrasound evaluation of the cervical length has been assessed (Krupa et al., 
2006) and found effective in predicting admission to delivery interval. Most 
important is their clinical usefulness in providing good negative predictive 
values (ACOG, 2005) .  
 No current data support use of home uterine activity monitoring or 
bacterial vaginosis screening (ACOG 2001, 2008). 
 
(3) Biochemical Markers (Odibo AO, Ural SH, Macones G, 2002) 
 More research is necessary to validate this approach and determine the 
predictive values and the cost effectiveness of this approach. These include: 
 Salivary estriol (McGregor JA , Jackson GM et al., 1995) 
 Progesterone 
 Serum collagenase 
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 Alpha fetoprotein 
 Tissue inhibitor of metalloproteinase (TIMP) / Matrix metalloproteinase 
 Relaxin 
 Corticotrophin releasing hormone (CRH) (McLean M , Smith R et al., 
1999) 
 Adrenocorticotrophic hormone (ACTH) 
 Prolactin 
 Thyroid stimulating hormone (TSH) 
 Alkaline phosphatase (ALP) 
 Serum ferritin, ferritin / Iron ratio 
 Human chorionic gonadotrophin (HCG) 
 
Mediators of inflammation and infection 
 C-Reactive Protein (CRP) 
 Leucocyte esterase  
 Granulocyte - colony stimulating factor 
 Cytokines (TNF-α , IL-1, IL-6) 
 Prostaglandins 
 Amniotic fluid glucose concentration 
 Zinc 
  Lipocortin – 1 
 Positive cultures 
  
The US National Institute of Child Health and Human Development 
Network of Maternal-Fetal Medicine Units (NICHD MFM Network) study 
 24 
showed that alpha fetoprotein , alkaline phosphatase and granulocyte-colony 
stimulating factor were the most promising biochemical markers (Goldenberg 
RL, Iams JD et al., 2001) 
 
DIAGNOSIS OF PRETERM LABOUR 
 The signs and symptoms of labour may appear only within 24 hours of 
preterm labour (Iams et al., 1994). 
 
(1) Symptoms 
 Pelvic pressure 
 Menstrual like cramps 
 Watery vaginal discharge 
 Low back pain 
 Painful or painless uterine contractions. 
Cervical changes in the presence of uterine contractions is the strongest 
indicator of preterm labour. 
 
(2) Clinical Examination 
Abdominal Examination  Uterine contractions at regular intervals 
Speculum examination 
(Sterile procedure to 
minimise risk of infection) 
 To determine the length of cervix and 
extent of dilatation of cervical os 
 To determine the presence of amniotic 
fluid 
Digital examination 
 To be avoided if membranes have 
ruptured, unless sufficient information was 
not obtained during speculum examination 
 Cervical effacement and dilatation are 
looked for. 
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(3) Role of ultrasound in preterm labour 
 Fetal viability 
 Number of fetuses 
 Placental localisation and morphology 
 Fetal presentation and lie 
Standard fetal biometry 
 Gestational age 
 Estimated fetal weight 
 Determine growth pattern (looking for FGR) 
Amniotic fluid index 
Fetal activity 
Indicators of preterm labour 
 Cervical length 
 Length of funnel 
 Width of the internal os 
 Cervical index 
Doppler Studies 
 Umbilical artery 
 Middle cerebral artery 
Rule out gross structural anomalies 
 Non viable fetal conditions 
 Markers for chromosomal abnormalities 
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(4) Tococardiography 
 Tococardiograph records uterine activity and fetal heart rate on a graph. 
The amplitude, duration, frequency of contractions and basal tone are 
monitored. The uterine activity is expressed in Montevideo units. 
 Changes in FHR reactivity in preterm labour is closely linked with the 
immaturity of autonomic nervous system of fetus. 
 
PREVENTION OF PRETERM LABOUR 
 Prevention of preterm birth has been an elusive goal. This requires 
timely and accurate screening of pregnant women for risk of preterm birth. 
Recent reports, however, suggest that prevention in selected population may be 
achievable. 
 
(1) Basic Care 
 Interventions like increased prenatal visits, patient education, home 
visits and nutritional counselling may play a role in reduction of preterm 
birth. 
 Rest and hydration. 
 Social and psychological support (Fiscella K et al., 1995). 
 Avoidance of heavy manual labour (Papiernik E , Collin D et al.,  
1985) and mental stress. 
 Behavioral & lifestyle modifications 
(a) Adequate nutrition 
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(b) Cessation of smoking (Abraham - Lerat L et al., 2004) 
(c) Avoidance of illicit drugs 
 
(2) Cervical Cerclage 
 With the emerging concept of a functional cervical insufficiency, the 
role of cervical cerclage for the prevention of preterm delivery is disputed. In 
2001, the Cervical Incompetence Prevention Randomised Cerclage Trial 
(CIPRACT trial) showed that patients with cervical insufficiency and cerclage 
placement (as compared to bed rest only) had a lower incidence of preterm 
delivery prior to 34 weeks in addition to lowered neonatal morbidity 
(Althuisius et al., 2001).  No benefit has been noted in twins (Dor et al., 1982) 
or in triplets (Roman et al., 2005). 
 
(3) Treatment of Cervicovaginal Infection 
 It has been postulated that intrauterine infection may trigger labour by 
activating the innate immune system (Goldenberg et al., 2008). A meta-
analysis by Morency and Bujold (2007) seemed to indicate that antibiotics 
given in the second trimester to women with a history of preterm labour would 
be effective in preventing recurrence of preterm labour. 
 Bacterial vaginosis has been consistently associated with a 1.5 to 3 times 
increased risk of spontaneous preterm birth (Goldenberg R and Rouse D et 
al., 1998), but the efficacy of treatment in reduction of preterm births is 
conflicting. A recent systematic review however concluded that screening and 
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treatment of asymptomatic bacteriuria and bacterial vaginosis in low risk 
population may reduce the rate of preterm deliveries (Varma R, Gupta JK, 
2006). 
 
(4) Progesterone 
 Weekly intramuscular injections of 250 mg of 17α-hydroxy-
progesterone caproate from 16-20 weeks gestation to 37 weeks for prevention 
of recurrent preterm birth has resulted in significant reduction in early preterm 
births and infant complications (Meis et al., 2003). So far there has been no 
reported increase in congenital anomalies (Resseguie LJ, Hick JF, 1985; 
Spong CY, 2003). Four year follow up found no adverse health outcomes of 
surviving children. 
 Use of micronised progesterone capsules (200 mg vaginally daily) for 
asymptomatic women with a very short cervix (less than 15 mm) between 24 
and 34 weeks of pregnancy appear to be effective (da Fonseca et al., 2007). 
 
MANAGEMENT OF PRETERM LABOUR 
(a) Bed Rest and Oral or Parenteral Hydration have traditionally been used 
in the management of preterm birth. 
Hydration may reduce uterine contractility by increasing uterine blood 
flow and by decreasing pituitary release of anti-diuretic hormone and oxytocin 
(Stan C, Boulvain M et al., 2002). A systematic review of the Cochrane 
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Database (Sosa et al., 2004) found no evidence to support or refute bed rest in 
preventing preterm birth. 
(b) Corticosteroid Therapy 
 The National Institute of Health Consensus Development 
Conference Statement in 1995, stated that ‘antenatal corticosteroid’ therapy is 
indicated for women at risk of preterm delivery. This will result in substantial 
decrease in neonatal morbidity and mortality, as well as substantial savings in 
health care costs. A systematic review of the Cochrane Database (Crowley, 
2003) confirmed that antenatal corticosteroids significantly reduced the 
incidence and severity of neonatal respiratory distress syndrome. 
 All women between 24 weeks and 34 weeks of gestation who are at risk 
of preterm delivery within 7 days are potential candidates for corticosteroid 
therapy (Ballard et al., 1995). Its effects on fetal intestine appear to be 
responsible for reduction in the risk of necrotising enterocolitis (NEC). 
 In addition, these neonates also have a reduced risk of intraventricular 
haemorrhage (IVH) (RCOG 2002). 
  Although the benefit on neonatal outcome is maximum between 24 
hours and seven days after initiation of therapy, steroids confer significant 
survival advantages even when delivery occurs within 24 hours. 
 
Betamethasone or Dexamethasone? 
 Band et al (1999) found betamethasone to be superior to dexamethasone in 
preventing RDS and periventricular leukomalacia. 
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Dosage 
Betamethasone 
 2 doses of 12 mg, given im 24 hours apart. 
Dexamethasone 
 4 doses of 6 mg, given im 12 hours apart (RCOG, 2004). 
 
“Rescue” Therapy 
Though the American College of Obstetricians and Gynaecologists  
(2008) recommends that a rescue dose be restricted to trials, McEvoy et al., 
(2010) showed that a rescue dose > / = 14 days after the last dose increased 
respiratory compliance in the treated infants. 
 
Single or Multiple Courses 
 A single course of antenatal corticosteroids is still considered standard 
of care (ACOG, 2008). Further studies are required before multiple doses can 
be recommended.  
 
(c) Antibiotics 
 Administration of antibiotics to the mother does not delay delivery 
(ORACLE Trial, 2001). A Cochrane meta-analysis by King and Flenady 
(2000) found no decrease in rates of newborn respiratory distress syndrome or 
of sepsis in antimicrobial treated groups. 
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(d) Tocolysis 
 Tocolytic drugs have been used in an attempt to inhibit preterm labour. 
Tocolytic drugs may prolong gestation for 24 to 48 hours, which can provide 
time for 
• the administration of antenatal steroids 
• inutero transfer of mother to a tertiary unit 
• to prepare for neonatal care (Merkatz et al., 1980; Guinn et al., 1997). 
As a general rule if tocolytics are given, they should be given 
concomitantly with corticosteroids. 
There appears to be a limited role for the use of tocolysis beyond 34 
weeks for the inhibition of preterm birth (Goldenberg, 2002). There is no first 
line tocolytic drug. The choice should be individualised and is usually based on 
maternal condition, potential drug side effects and gestational age (ACOG, 
2003). 
(1) Beta Adrenergic Receptor Agonists 
 The commonly used beta sympathomimetic drugs are ritodrine, 
terbutaline and salbutamol. In terms of clinical effectiveness the inhibition of 
contractions by β-adrenergic agonists is often short lived. 
 Ritodrine infusion is started at a dose of 50 mcg / min and increased 
every 20 minutes until uterus is quiescent or side effects limit escalation of 
dose. The maximum recommended infusion rate is 350 mcg / min. The RCOG 
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no longer recommends ritodrine as the first drug of choice (RCOG Clinical 
Guidelines, 2002). 
 Terbutaline has not been used as much as ritodrine, but is effective in 
temporarily arresting contractions when given parenterally. 
Route Regimen 
Oral 2.5 - 5 mg every 4 - 6 hours 
Subcutaneous 250 mcg s.c. every 20-30 minutes × 4-6 doses 
Intravenous 
5-10 mcg / min increased every 10-15 
minutes to a  
maximum of 80 mcg / min 
 
Side effects 
 Palpitations, tremor, nausea, headache 
 Myocardial ischemia 
 Cardiac arrhythmias 
 Pulmonary edema 
 Metabolic derangements – hyperglycemia, hypokalemia 
 Fetal tachycardia and neonatal hypoglycemia. 
 
Contraindications 
 Symptomatic cardiac disease, especially ventricular outflow obstruction. 
 Symptomatic cardiac rhythm or conduction disturbances. 
 Hyperthyroidism 
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 Sickle cell disease 
 Uncontrolled insulin - dependent diabetes mellitus 
 Chorioamnionitis 
 Eclampsia or severe preeclampsia 
 Severe anaemia 
 Multifetal gestation 
 Psychiatric patients on MAO inhibitors 
 Asthmatic patients already on β-adrenergic agents. 
 
(2) Nonsteroidal Anti-inflammatory Agents 
 Drugs like indomethacin, aspirin, ibuprofen and sulindac belong to this 
group, of which indomethacin has been used the most. Comparison with beta-
agonists show similar efficacy, but a better side effect profile (RCOG Clinical 
Guidelines, 2002). 
 Prostaglandin synthetase inhibitors are highly effective in inhibiting 
myometrial activity, a single dose being effective in many women at term 
(Reiss et al., 1976). 
 
Side Effects   
Maternal 
 Headache 
 Dizziness 
 Gastritis, Vomiting 
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 Asthma recurrence 
 Diarrhoea 
 Thrombocytopenia 
 
Fetal 
 Constriction of ductus arteriosus 
 Persistent fetal circulation 
 Hydrops 
 Oligohydramnios 
 Bleeding disorders 
 Necrotising enterocolitis / ileal perforation 
 Intraventricular haemorrhage (grade III, IV) 
All these fetal side effects have restricted their use. 
 
(3) Oxytocin Receptor Antagonist (Atosiban) 
 This nonapeptide oxytocin analog is a competitive antagonist of 
oxytocin induced contractions. Duration of treatment should not exceed 48 
hours and the total dose given should not exceed 330 mg of atosiban. 
 Compared to beta-agonists, atosiban was found to have comparable 
efficacy & fewer side effects. Side effects include nausea, chest pain, headache, 
vomiting, dyspnoea and injection site reactions. Last generation of oxytocin 
receptor antagonists such as barusiban would be more efficient and have less 
affinity for the vasopressin receptors.  
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 The Food and Drug Administration has denied its approval because of 
concerns regarding efficacy and fetal-newborn safety. Its high cost is also a 
factor limiting its use in developing countries. 
 
(4) Nitric Oxide Donors (Glyceryl Trinitrate) 
 Nitric oxide is a potent endogenous hormone causing smooth muscle 
relaxation. Nitroglycerine, a nitric oxide donor has been used for the treatment 
of preterm labour. Cochrane review (2002) showed that nitroglycerine did not 
delay delivery nor improve neonatal outcome (Duckitt et al). 
 Nitric oxide is generated from the oxidation of L-arginine by NO 
synthase. Nitric oxide increases cyclic guanosine monophosphate levels, 
leading to inactivation of the myosin light chain kinases, causing smooth 
muscle relaxation. 
10 mg of glyceryl trinitrate patch is applied over the fundal region of 
maternal abdomen. If tocolysis is not achieved in one hour, another 10 mg 
patch can be applied to a maximum dose of 20 mg in 24 hours. 
Side effects were fewer when compared to other tocolytics, but the 
incidence of headache and hypotension were high (Bisits et al., 2004). 
Currently there is not enough evidence to recommend nitroglycerine for routine 
clinical practice. 
 
(5) Potassium Channel Openers 
Diazoxide is a medication structurally related to the thiazide diuretics 
that is used in the treatment of hypertensive crisis. The drug inhibits 
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genitourinary smooth muscle and is responsible for its effectiveness as a 
tocolytic agent. 
 The dosage of diazoxide is 5 mg / kg given intravenously slowly in 15-
30 minutes. It can also be given as boluses of 50-100 mg every 5 minutes. 
 The most common maternal side effects are hypotension, tachycardia, 
hyperglycemia and decreased uteroplacental blood flow. Fetal side effects are 
hyperglycemia and fetal distress.  
 Potassium channel openers under study are Pinacidil and 
Leveromalkim. Further studies of this group of tocolytic drugs is needed. 
 
(6) Magnesium Sulphate 
 Prior to 1980s magnesium sulphate was widely used in the United States 
in the intrapartum management of preeclampsia and eclampsia and the clinical 
impression that magnesium sulphate made induction of labour more difficult 
lead to its evaluation as a tocolytic agent and is in common use now. 
 Magnesium sulphate has been shown to cause myorelaxation. Its role is 
presumably that of a calcium antagonist. 
 
Pharmacology 
 Magnesium sulphate USP is MgSO4.7H2O 
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 It has a molecular weight of 24.3. 
 1 gram of magnesium sulphate has 98 mg of elemental magnesium. 
 
Mechanism of action 
  The exact mechanism by which magnesium sulphate acts is unknown. It 
is proposed that it inhibits myometrial contractions by antagonizing calcium at 
the cellular level and in the extracellular space, reducing intracellular levels of 
calcium and preventing activation of actin-myosin complexes in smooth 
muscle. Magnesium may also act directly on calcium channels by competing 
for binding sites.  
 
Proposed mechanisms  
 Blockage of calcium entry via voltage gated channels (Arango and 
Mejia – Mantilla, 2006). 
 Improved mitochondrial calcium buffering. 
 Potentiation of adenosine action. 
 Blockage of glutaminergic N-methyl-D-aspartate (NMDA) receptors. 
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Other actions 
 Vasodilatation in vascular beds. 
 Decrease in systemic vascular resistance and mean arterial pressure. 
 Increased uterine blood flow. 
 Increased renal blood flow. 
 
Pharmacological effects 
 Decrease in the frequency and intensity of uterine contractions and slow 
cervical dilatation. 
 Anti-convulsant action. 
 Transient hypotensive effect 
 
Administration 
Zuspan’s Regime 
Loading dose 
 4g of 20% MgSO4 given intravenously over 5-10 minutes, at a rate not 
exceeding 1g / min (Cunningham et al., 2010). 
Maintenance dose 
This is followed by an infusion of 1-2 g / hr in 50-100 ml of iv 
maintenance solution (NS) by controlled infusion pump (RCOG, 2006). 
  
 Once the uterus is relaxed, the infusion rate is maintained at its lowest 
effective rate for 12-24 hours and then weaned off. 
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Steer and Petrie (1977) concluded that intravenously administered 
magnesium sulphate, a 4 g loading dose followed by a continuous infusion of 
1-2 g/hr  usually arrest labour. 
 
Monitoring of MgSO4 therapy 
 After the initial loading dose, repeat doses should be given only if 
 Patellar reflex is present 
 Respiratory rate > 16 / min 
 Urine output > 100 ml in the preceding 4 hours. 
 Auscultation of lung bases and pulse oxymetry also play an important 
role 
 Duley et al (1995) in his study showed that there is no need to check 
serum magnesium levels. 
 
Side Effects 
Maternal 
 Subjective – flushing, nausea, vomiting, headache, blurred vision, 
generalised weakness 
 Muscular weakness 
 Pulmonary congestion 
 Respiratory depression 
 Neurotoxicity 
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Elliot’s study (1983) of maternal side effects found that side effects 
occurred in 7% of patients and necessitated stopping treatment in 2% with 
pulmonary edema occuring in 1% of patients. 
The side effect profile is relatively better compared to ritodrine.  
 
Fetal  
 Maternal levels rapidly equilibrate with fetal plasma and the 
concentration in both compartments are similar. 
It causes transient decrease in FHR variability during labour. 
 
Neonatal   
 Respiratory depression 
 Hyporeflexia 
 Hypotonia 
 Low apgar scores 
 Doyle and co-workers (2009) reported that magnesium exposure is 
neuroprotective, if received for 24 hours (RCOG Greentop Guidelines, 2011) 
and decreased the risks of cerebral palsy in very low birth weight infants. 
 
Toxicity 
 Toxicity is however rare in clinical practice, provided the drug is 
administered with proper monitoring. The first sign of impending toxicity 
occurs with loss of patellar reflex. The drug must be discontinued until patellar 
reflex is present. 
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Signs & Symptoms of Magnesium Toxicity 
Blood levels Signs & Symptoms 
4-8 mg / dl Therapeutic 
9-12 mg / dl Nausea, Warmth, flushing, somnolence, double vision, 
slurred speech, weakness and loss of patellar reflex 
15-17 mg / dl Muscular paralysis, respiratory arrest 
30-35 mg / dl Cardiac arrest 
 
Pharmacological doses that inhibit myometrial contractions are achieved 
at levels of 5-8 mg / dl.  
Toxicity is also associated with decreased myometrial activity and 
increased blood loss at delivery. 
 
Management of toxicity 
 An excellent marker of magnesium toxicity is pulse oxymetry (≤ 96%). 
 Mild to moderate respiratory depression or neuromuscular toxicity. 
 Usually reversible. 
 Infusion is discontinued immediately. 
 Oxygen should be administered (8 to 10 litres / min). 
 Monitor vital signs. 
 IV calcium gluconate 10 ml of a 10% solution given over 3 minutes or  
1 g iv infused slowly over a period of 3 minutes. 
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Clearance      4.28 L / Hr 
Ca++ antagonises the effect of magnesium by increasing the amount of 
acetylcholine liberated by the action potentials at the neuromuscular junction. 
 Check serum magnesium and creatinine levels. 
For severe respiratory depression and arrest prompt tracheal intubation 
and mechanical ventilation are life saving. 
 
Contraindications 
 Myasthenia gravis 
 Heart block 
 Renal disease 
 Recent MI 
 
Distribution 
 About 40% of plasma magnesium is protein bound. The unbound 
magnesium ion diffuses into the extravascular space, into bone, skeletal 
muscle, across the placenta and fetal membranes and into the fetus and 
amniotic fluid. In pregnant women, apparent volumes of distribution usually 
reach constant values between the third and fourth hour after administration. 
 
Volume of distribution of magnesium  0.25-0.44 L / Kg 
Half life      5 to 6 Hours 
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Excretion 
 Magnesium is excreted almost solely by kidneys. 50% of infused dose is 
excreted after 4 hours in urine. 90% of the bolus intravenous dose is excreted 
within 24 hours. 
 Since magnesium is eliminated by kidneys monitoring of urine output is 
extremely important. Magnesium intoxication is unusual when GFR is 
maintained. 
 The initial 4 g loading dose of MgSO4 can be safely administered. Only 
the maintenance infusion rate should be altered with diminished GFR. If serum 
creatinine > 1 mg / dl serum magnesium levels are used to adjust the infusion 
rate. 
 
Drug Interactions with Magnesium Sulphate 
Agent Effect Recommendation 
Depolarising / 
nondepolarising 
neuromuscular 
blockers 
Increased activity of 
these agents 
May need dosage reduction 
CNS depressants Additive CNS 
depression 
May need dosage reduction 
Nifedipine Hypotension Administer with caution and 
adjust nifedipine dosage if 
necessary 
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(6) Calcium Channel Blockers 
 Myometrial activity is directly related to cytoplasmic free calcium and a 
reduction in its concentration inhibits contraction. Calcium channel blockers 
act to inhibit, by a variety of mechanisms, the entry of calcium through 
channels in the cell membrane. 
 The most common calcium channel blocker used is nifedipine. 
Nifedipine is a 1,4-dihydropyridine. 
 
 
Mechanism of action 
 Nifedipine inhibits the influx of extracellular calcium across the cell 
membrane during inward calcium current of action potential by blocking slow 
voltage dependent L-type channels regulating calcium influx. It also inhibits 
the release of intracellular calcium from the sarcoplasmic reticulum. Since less 
intracellular calcium is available for binding to myosin light chain kinase and 
Structure of Nifedipine 
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formation of calcium - calmodulin complex, phosphorylation of actin- myosin 
apparatus is inhibited, thereby reducing the contractility of smooth muscles. 
 
Side Effects 
 Dizziness 
 Palpitations, tachycardia 
 Transient hypotension 
 Headache 
 Flushing 
 Nausea 
 Peripheral edema 
 Fetal hypoxia 
All the adverse effects are a consequence of vasodilatation. Severe side 
effects are extremely rare (Hauretty et al., 1989). 
 
Contraindications 
 Hypotension 
 Congestive cardiac failure 
 Aortic stenosis 
 Used with caution in diabetes or multiple pregnancy (British National 
Formulatory) 
Nifedipine has been compared to beta agonists in several randomised 
studies which suggest that calcium antagonists are more effective, better 
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tolerated with fewer side effects and have lower neonatal morbidity (King et 
al., 2003). Its main advantages include fewer metabolic and cardiovascular 
complications. No significant change in uteroplacental flow has been reported 
with nifedipine. 
 
Administration 
 There is no consensus on dosage or frequency for tocolysis with 
nifedipine. Commonly recommended protocol consists of 
 20 mg orally stat 
 Followed by 20 mg orally after 30 minutes if contractions persist 
 Maintenance dose of 10-20 mg orally every 6-8 hours 
 Maximum dose is 160 mg / day 
 
Tocolytic regimen given in Obstetrics and Gynaecology Clinics of 
North America is a loading dose of 30 mg orally followed by maintenance 
dose of 10-20 mg orally every 4-6 hours. BP should be monitored carefully. 
Sublingual route is not recommended because of risk of sudden hypotension. 
 
Pharmacokinetics 
Absorption 
 Nifedipine is absorbed rapidly from the oral mucosa and from 
gastrointestinal tract, with detectable levels within minutes of administration. 
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Bioavailability   30-60% 
Onset of action   < 20 minutes 
Peak plasma concentration  1 hour (15-90 minutes) 
Elimination t½  2-5 hours (Ferguson et al., 1989) 
Duration of action of a single dose 6 hours 
 
Distribution 
 
 
 
Metabolism 
More than 90% of the drug is metabolised in liver. 
Elimination 
Nifedipine is eliminated mainly through kidneys (70%) and bowels 
(30%) (Amy et al.). 
The combination of nifedipine with magnesium for tocolysis is 
potentially dangerous. Ben Ami and Co-workers (1994) and Kurtzman and 
associates (1993) reported that nifedipine enhances neuromuscular blocking 
effects of magnesium that can interfere with pulmonary and cardiac function. 
Co-administration of calcium channel blockers with magnesium sulphate can 
cause hypotension (John Studd, Vol 17; ACOG, 2003). 
 Lyell and Colleagues (2007) found no substantial differences in 
efficacy or adverse effects between nifedipine and magnesium sulphate. 
Volume of distribution  0.8 L / Kg 
Clearance    0.42 L / Hr 
 
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
This is a prospective randomised controlled trial, conducted in the 
labour ward of Mahatma Gandhi Memorial Government Hospital, Trichy 
between July 2011 and June 2012. 
The study population comprised of 100 patients, randomly assigned to 
intravenous magnesium sulphate and another 100 patients assigned to oral 
nifedipine. Both the groups had bed rest and received intramuscular 
corticosteroids. All the patients were counselled and informed consent was 
obtained. 
 
INCLUSION CRITERIA 
1. Gestational age between 28 and 34 weeks as determined by last 
menstrual period, clinical examination and USG. 
2. Uterine contractions - 4 contractions in 20 minute period, each 
contraction lasting for 40 seconds. 
3. Progressive cervical effacement ≤ 75%  
4. Cervical dilatation ≤ 3cm 
5. Intact membranes 
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EXCLUSION CRITERIA 
Maternal Factors 
1. Ruptured membranes 
2. Infection / chorioamnionitis 
3. Cervical dilatation  > 3cm 
4. Antepartum haemorrhage  
5. Hypertensive disorders of pregnancy 
6. Disorders of amniotic fluid volume 
7. Previous caesarean section  
8. Cardiac disease 
9. Renal disease 
10.  Pulmonary disorders – Asthma, ARDS 
11. Uncontrolled diabetes mellitus 
12.  Hyperthyroidism 
13. Any contraindication for use of  nifedipine or magnesium 
14. Presence of cerclage 
15. Tocolytic use within the last 12 hours 
16. Hypotension ( defined as average BP of < 90/60 mm Hg unresponsive to 
1000cc of fluid bolus ) 
 
Fetal Factors 
1. Fetal death 
2. Nonreassuring fetal heart tracing 
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3. Lethal congenital or chromosomal abnormalities  
4. Fetal growth restriction 
5. Erythroblastosis fetalis  
6. Multiple pregnancy 
 
INVESTIGATIONS 
1. Urine  Analysis 
2. Complete blood count 
3. Blood Sugar 
4. Renal function tests 
(Blood urea, Serum creatinine) 
5. Vaginal swab 
6. ECG 
7. CTG 
8. USG 
 
DRUG PROTOCOL 
In all the patients detailed obstetric and medical history were elicited. 
They were asked to lie in left lateral position. Vital parameters (pulse rate, 
blood pressure, respiratory rate and temperature) were recorded. 
Cardiovascular and respiratory system were examined. Detailed obstetric 
examination was done. 
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Side effects of both the drugs were documented. Maternal outcome till 
discharge was noted. 
 
Group A 
Intravenous Magnesium Sulphate 
Loading Dose 
4g of 20% Mg So4 given intravenously over 5-10 minutes, at a rate not 
exceeding 1g/minute. 
Maintenance Dose 
This is followed by an infusion of 1g/hour in 50ml of NS by controlled 
infusion pump.  
 Once the uterus is relaxed, the infusion is maintained for 12 hours and 
then weaned off. The incidence of pulmonary edema is less if the total volume 
of intravenous infusion is limited to < 1000ml / day 
Monitoring 
After the initial loading dose, treatment is discontinued if 
• Patellar reflex is absent 
• Respiratory rate < 16/min 
• Urine output < 100ml in the preceding 4 hours 
• Oxygen saturation ≤ 96% 
 All these parameters were monitored every 2 hours. Uterine contractions 
were monitored every 30 minutes for the first 2 hours, then every 4 hours for 
48 hours. 
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 Magnesium sulphate treatment was defined as effective if the uterine 
contractions were reduced more than 30% in frequency and intensity compared 
to those occurring during the last two hours before magnesium sulphate 
infusion. Treatment was defined as ineffective if uterine contractions were not 
reduced by 30% and labour progressed with apparent changes in cervical 
findings. 
 
Group B 
Oral Nifedipine 
 Tablet Nifedipine 20mg orally stat was given. This was followed by 
20mg orally after 30 minutes if contractions persist. Maintenance dose of 10mg 
orally 8th hrly was continued for 48hours. 
Monitoring 
Maternal     Fetal 
Pulse Rate     Hearth Rate 
Blood Pressure    Rhythm 
Uterine Contractions   Tone 
All were monitored every 30 minutes for the first 2 hours, then every 4 
hours for 48 hours. 
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Treatment is discontinued if 
• Systolic BP < 100 mmHg 
• Pulse rate  > 100 b/min 
• Fetal heart rate  > 180 b/min 
Steroids 
Given for both group A & Group B 
Betamethasone  
2 doses of 12mg, given im 24 hours apart. 
Prophylactic antibiotics were also given for both the groups 
 
RESPONSE TO TOCOLYTIC THERAPY 
Definition of Success 
 Various authors have considered several factors for assessing the 
success of tocolysis. 
 Successful tocolysis was defined when uterine contractions subsided and 
delivery was delayed for more than 48 hours. 
Definition of failure 
 Failure of tocolysis was defined as persistent uterine contractions, 
despite maximum dose and delivery occurring in the first 48 hours of initiation 
of therapy. 
 This study confines itself to idiopathic spontaneous preterm labour, 
comparing the safety and efficacy of intravenous magnesium sulphate with that 
of oral nifedipine in acute tocolysis for corticosteroid therapy and to study the 
maternal and fetal effects.  
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All the data were entered prospectively in a predefined data information 
sheet and analysed. The Statistical Package for the Social Sciences (SPSS) was 
used for analysis of all data. 
Difference is categorical and continuous data were assessed using the 
chi square test and students ‘t’ test respectively.  
 
p – values 
 When we compare the calculated probability (p) with the level of 
significance, if it is less than 0.05 (p < 0.05) or 0.01 (p < 0.01), there is 
significant difference between the two sample populations. If the calculated p is 
equal to or greater than 0.05 (p ≥ 0.05) or 0.01 (p ≥ 0.01), there is no significant 
difference between the two. A statistical test is said to be significant if the p-
value is less than the significance level (0.05 or 0.01). 
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ANALYSIS OF RESULTS 
TABLE – 1 
AGE DISTRIBUTION 
Group A Group B 
Age (Yrs) 
Number % Number % 
< 20 7 7% 7 7% 
20 – 24 45 45% 43 43% 
25 – 29 34 34% 35 35% 
≥ 30 14 14% 15 15% 
Total 100 100% 100 100% 
χ2 =27.27 χ2 =59.89 
Statistical Value 
t = 2.77 p = 0.487 
 
There was no significant difference in the age distribution of both the 
groups of patients. 
Majority of patients (44%) fell into the age group of 20-24 years. 
7% of patients fell into the age group of < 20 years and 14.5% into the 
age group of ≥ 30years on an average. 
The study subjects had a mean age of 23.2 years. 
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TABLE - 2 
SOCIOECONOMIC STATUS 
Group A Group B Socioeconomic 
Status Number % Number % 
V 59 59% 62 62% 
IV 24 24% 25 25% 
III 17 17% 13 13% 
Total 100 100% 100 100% 
χ2 =18.43 χ2 =23.11 
Statistical Value 
t = 2.54 p = 0.126 
 
 
None of the patients in this study belonged to class I and II 
socioeconomic status. 
On an average, majority (60.5%) of the patients belonged to Class V 
socioeconomic status. The rest of them belonged to class IV and class III socio- 
economic status. There was no significant difference between the groups. 
Low socioeconomic status is one of the important demographic factors 
associated with high risk of preterm labour. 
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TABLE - 3 
OBSTETRIC CODE 
Group A Group B Obstetric Code Number % Number % 
Primi 60 60% 54 54% 
G2 30 30% 24 24% 
G3 7 7% 16 16% 
G4 3 3% 6 6% 
Total 100 100% 100 100% 
SD = 67.88 SD =66.46 Statistical Value 
t = 1.063 p = 0.480 
 
  
Parity was comparable in both the groups of patients. There was no 
significant difference. 
60% of patients in group A and 54% of patients in group B were 
primigravida. 40% of patients in group A and 46% of patients in group B were 
multigravida. 
There is a higher incidence of preterm labour in first pregnancies. 
OBSTETRIC CODE 
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TABLE - 4 
BOOKING STATUS 
Group A Group B 
Booking Status 
Number % Number % 
Booked 43 43% 46 46% 
Unbooked 57 57% 54 54% 
Total 100 100% 100 100% 
SD = 66.85 SD =63.47 
Statistical Value 
t = 1.20 p = 0.312 
 
 
Antenatal booking status did not differ significantly among both the 
groups of patients. 
57% of patients in Group A and 54% in Group B were unbooked. In 
patients with no antenatal care preterm labour was more common. 
BOOKING STATUS 
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TABLE - 5 
GESTATIONAL AGE 
Group A Group B Gestational Age Number % Number % 
28 – 30 wks 26 26% 29 29% 
31 – 32 wks 35 35% 29 29% 
33 – 34 wks 39 39% 42 42% 
Total 100 100% 100 100% 
χ2 =18.43 χ2 =49.66 Statistical Value 
t = 1.93 p = 0.03 
 
Treatment delivery interval varied significantly with gestational age at 
the time of admission in both the groups of patients. 
On an average, majority of patients in both the groups ( 40.5%)  had a 
gestational age of 33-34 weeks, with a better neonatal outcome. 32% of 
patients belonged to gestational age group of 31-32 weeks. 27.5% of patients 
belonged to gestational age group of 28-30 weeks. 
Late preterm labour is more common than early preterm labour. 
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TABLE - 6 
PAST OBSTETRIC HISTORY 
Group A Group B 
Past Obstetric History 
Number % Number % 
History of preterm labour 9 9% 8 8% 
History of 2nd trimester  
abortion 6 6% 4 4% 
SD = 20.84 SD = 22.72 
Statistical Value 
t = 12.66 p = 0.300 
 
Majority of patients in both the groups were primigravida and 
experienced preterm labour for the first time. There was no significant 
difference in the past obstetric history among both the groups of patients. 
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TABLE - 7 
MATERNAL SIDE EFFECTS 
 
 
Group A 
 Flushing was the commonest side effect in patients who received 
intravenous magnesium sulphate. Majority of patients in this group developed 
minor side effects. Two patients developed pulmonary edema, requiring 
treatment discontinuation and both delivered at <48 hours. 
None of the patients developed signs and symptoms of toxicity. No case 
of postpartum haemorrhage was observed in those who delivered within 48 
hours. 
 
Group B 
 No severe adverse effects were noted except hypotension that developed 
in 2 patients requiring treatment discontinuation and one among them delivered 
at < 48 hrs. 
 There was no maternal mortality among both the groups of patients. 
Group A Group B Side Effects Number % Side Effects Number % 
Flushing 21 21% Headache 14 14% 
Headache 09 09% Dizziness 9 9% 
Nausea / Vomiting 09 09% Palpitations 5 5% 
Drowsiness 11 11% Hypotension 2 2% 
Pulmonary Edema 02 02% Nausea / Vomiting 5 5% 
Total 52 52% Total 35 35% 
Statistical Value t = 2.48  t = 2.487 
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TABLE - 8 
PRESENTATION 
Group A Group B 
Presentation 
Number % Number % 
Cephalic 85 85% 87 87% 
Breech 13 13% 11 11% 
Transverse Lie 2 2% 02 02% 
Total 100 100% 100 100% 
SD = 85.10 SD = 67.88 
Statistical Value 
t = 10.40 p = 0.487 
 
Majority of patients in both the groups were in cephalic presentation. 
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TABLE - 9 
CERVICAL EFFACEMENT 
Group A Group B Cervical 
Effacement Total 
No. Success Failure 
Total 
No. Success Failure 
25% 29 25(86.2%) 4(13.8%) 35 35(100%) - 
50% 56 34(60.7%) 22(39.3%) 42 36(85.7%) 6(14.3%) 
75% 15 3(20%) 12(80%) 23 12(52.2%) 11(47.8%) 
Total 100 62 38 100 83 17 
Statistical 
Value SD = 25.71  p = 0.0031 
 
In patients with 25% cervical effacement, 86.2% of patients in Group A 
and 100% of patients in Group B had successful tocolysis. With 50% cervical 
effacement, prolongation of pregnancy was observed in 60.7% of patients in 
Group A and 85.7% of patients in Group B. In patients with 75% cervical 
effacement 20% of patients in Group A and 52.2% in group B had their 
pregnancy prolonged by more than 48 hours,  which is statistically highly 
significant (p = 0.0031). 
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TABLE - 10 
CERVICAL DILATATION 
Group A Group B  Cervical 
Dilatation 
 
Total 
No. Success Failure 
Total 
No. Success Failure 
1cm 44 35(79.5%) 9(20.5%) 37 36(97.3%) 1(2.7%) 
2 cm 52 27(52%) 25(48%) 54 41(76%) 13(24%) 
3 cm 4 - 4(100%) 9 6(66.7%) 3(33.3%) 
Total 100 62 38 100 83 17 
Statistical 
Value SD = 12.02  p = 0.0012 
 
When the cervix was 1cm dilated 79.5% of patients in group A and 
97.3% of patients in group B had successful tocolysis. With 2cm cervical 
dilatation successful tocolysis was observed in 52% in group A and 76% in 
group B. And when cervix was 3cm dilated prolongation of pregnancy > 48hrs 
was observed in none of the patients in group A and 66.7% of patients in group 
B which is statistically highly significant (p = 0.0012). 
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TABLE - 11 
SUCCESS OF ACUTE TOCOLYSIS 
Group A Group B 
Duration 
Number % Number % 
< 48 hrs 38 38% 17 17% 
> 48 hrs 62 62% 83 83% 
Total 100 100% 100 100% 
χ2 =19.36 χ2 =21.36 
Statistical Value 
t = 21.32 p = 0.003 
 
Acute tocolysis was successful in 62% of patients in group A and 83% 
of patients in group B, which is statistically highly significant (p = 0.003) 
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TABLE - 12 
DURATION OF PROLONGATION 
Group A Group B Prolongation 
Period Number % Number % 
< 48 hrs 38 38% 17 17% 
48 - 72 hrs 28 28% 31 31% 
72 hrs - 1 wk 21 21% 34 34% 
1 -2 wks 10 10% 12 12% 
> 2 wks 3 3% 6 6% 
Total 100 100% 100 100% 
χ2 =61.76 χ2 =62.06 Statistical Value 
t = 13.65 p = 0.000 
 
Among the success group, prolongation of pregnancy beyond 72 hrs was 
observed in 21% in group A and 34% in group B. Prolongation beyond 1 week 
was observed in 10% in group A and 12% in group B, beyond 2 weeks in 3% 
in group A and 6% in group B which is statistically highly significant 
(p=0.000). 
Mean duration of prolongation of pregnancy was 1.8 days and 4.29 days 
in group A and group B respectively. 
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TABLE - 13 
PROLONGATION OF PREGNANCY 
Group A Group B 
Gestational Age 
Number % Number % 
< 37 wks 97 97% 94 94% 
> 37 wks 3 3% 6 6% 
Total 100 100% 100 100% 
χ2 =66.36 χ2 =65.66 
Statistical Value 
t = 19.43 p = 0.000 
 
Prolongation of pregnancy beyond 37 weeks was observed in 3% of 
patients in group A and 6% of patients in group B, which is statistically highly 
significant (p = 0.000). 
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TABLE - 14 
RESPONSE ACCORDING TO GESTATIONAL AGE 
Group A Group B Gestational 
Age Number Success Failure Number Success Failure 
28-30 wks 26 13(50%) 13(50%) 29 19(65.5%) 10(35.5%) 
31-32 wks 35 22(62.8%) 13(37.2%) 29 25(86.2%) 4(13.8%) 
33-34 wks 39 27(69.2%) 12(30.8%) 42 39(92.8%) 3(7.2%) 
Total 100 62 38 100 83 17 
SD = 
12.44 χ
2 
=16.32 SD = 12.44 χ
2 
=21.44 Statistical 
Value 
p = 0.003  t=1.872 
 
Between 33 and 34 weeks of gestation tocolysis was successful in 
69.2% of patients in group A and 92.8% of patients in group B which is 
statistically highly significant (p = 0.003). 
Even at earlier gestational age it was successful in more number of 
patients in group B, when compared to group A. 
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TABLE – 15 
DOSE REQUIRED TO STOP CONTRACTIONS AMONG SUCCESS  
GROUP 
Group A 
Dose of MgSo4  Number % 
4g 2 3.22% 
8g 3 4.80% 
12g 5 8.10% 
16g 30 48.40% 
> 16g 22 35.48% 
Total 62 100% 
Statistical Value t = 1.493 
 
 
Group B 
Dose of nifedipine  Number % 
20 mg 40 48.2% 
40 mg 37 44.6% 
50 mg 6 7.2% 
Total 83 100% 
Statistical Value t =  7.518 
 
Group A 
Among the success group, majority of patients in group A (48.4%) 
required 16g of MgSO4 to stop contractions. 3.22% required  4g, 4.8% required 
8g, 8.10% required 12g and 35.48% of patients required > 16g to stop uterine 
contractions. 
 
Group B 
In group B, 48.2% of patients required 20mg, 44.6% required 40mg and 
7.2% required 50mg of nifedipine to stop uterine contractions. 
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TABLE – 16 
MODE OF DELIVERY 
Group A Group B 
Mode of Delivery 
Number % Number % 
Vaginal 98 98% 97 97% 
Caesarean Section 2 2% 3 3% 
Total 100 100% 100 100% 
Statistical Value t = 1.042 t = 1.064 
 
98% and 97% of patients delivered vaginally in group A and group B 
respectively. 2% of patients in group A and 3% of patients in group B 
underwent caesarean section for transverse lie and breech presentation. 
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TABLE – 17 
APGAR SCORE 
Group A Group B 5’ Apgar 
 Success Failure Success Failure 
< 5 7 (11.2%) 21 (55.2%) 6 (7.2%) 9 (53%) 
5 – 7 16 (25.8%) 12 (31.5%) 18 (21.6%) 5 (29.4%) 
> 7 39 (63%) 5 (13.3%) 59 (71.2%) 3 (17.6%) 
Total 62 38 83 17 
χ2 = 74.23 χ2 = 77.63 Statistical Value 
t = 19.55 p = 0.000  
 
Apgar score of >7 was found in 76.3% of babies in group A and 88.8% 
of babies in group B, which is statistically highly significant (p = 0.000). 
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TABLE – 18 
BIRTH WEIGHT OF BABY 
Group A Group B Weight of baby (kg) Number % Number % 
< 2  44 44% 36 36% 
2 – 2.5  53 53% 58 58% 
> 2.5  3 3% 6 6% 
Total 100 100% 100 100% 
χ2 = 25.73 χ2 = 31.67 Statistical Value 
t = 1.008 p = 0.000  
 
 Majority of the babies had a birth weight of 2 - 2.5kg in both the groups. 
6% of babies in group B had a birth weight > 2.5kg, compared to 3% in 
group A which is statistically highly significant (p=0.000) 
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TABLE – 19 
NEONATAL MORBIDITY 
Complication Group A Group B 
I – Hypothermia 13 9 
II – RDS/Apnoea of immaturity 12 6 
III – Sepsis 7 3 
IV – Feeding problems 20 14 
V – hyperbilirubinemia 22 16 
VI – Intraventricular haemorrhage 3 2 
SD = 19.33  SD =18.67 Statistical Value 
p = 0.001 
 
Some of the most common complications of preterm babies have been 
studied. 
RDS, sepsis and intraventricular haemorrhage which are the most 
worrisome complications of preterm babies were found less commonly in 
group B, compared to group A and is statistically highly significant (p = 0.001). 
In group A, hypotonia and hyporeflexia were observed in 5 babies, 
respiratory depression in 2 babies and apgar score < 5 in 28 babies. 
Fetal tachycardia was observed in 2 patients in group B and FHR 
returned to baseline values 3 hours after commencing therapy.   
 
NEONATAL MORBIDITY 
13
9
12
6
7
3
20
14
22
16
3
2
0
5
10
15
20
25
Pe
rc
en
ta
ge
I II III IV V VI
Complication
Group A Group B
 
 75 
TABLE – 20 
NEONATAL MORTALITY 
Group A Group B Neonatal 
mortality  Number % Number % 
< 48 hrs 16 42.1% 6 35.2% 
> 48 hrs 5 8% 4 4.8% 
Total 21  10  
SD = 38.61 χ2 = 38.001 
Statistical Value 
t = 19.01 p = 0.000  
 
In success group, neonatal mortality was 8% in group A and 4.8% in 
group B. In failure group it was 42.1% in group A and 35.2% in group B which 
is statistically highly significant (p = 0.000) 
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DISCUSSION 
 
Preterm labour and delivery accounts for major proportion of neonatal 
deaths. The goal of therapy of preterm labour is the drug which is effective and 
with minimum adverse effects. 
In our study maternal demographic and clinical characteristics at 
randomisation were similar between the 2 groups regarding maternal age, 
socioeconomic status, parity, booking status, gestational age at admission and 
past obstetric history. Similarly vaginal and caesarean delivery rates were not 
significantly different. 
 In each study group, the gestational age at admission varied 
considerably. In our study the gestational age range was between 28 and 34 
weeks. There is no consensus on a lower gestational age limit for the use of 
tocolytic agents. In a study conducted by Krishna et.al (1996), gestational age 
at admission varied from 18-34 weeks. In another study done by Lyell DJ et al 
(2011) patients in the gestational age group of 24-34 weeks were assigned 
randomly to magnesium sulphate or nifedipine. Several metaanalysis excluded 
women with cervical dilatation of more than 4cm, while in our study the limit 
was 3cm. 
Significant difference between the 2 groups was found in prolongation 
time after tocolytic administration, gestational age at delivery, incidence of low 
apgar scores, difference in birth weight and time spent by the newborn in NICU 
as in the study conducted by Yasuyuki Kawagoe et al (2011). 
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In a study conducted by Ali Akbar Taherian et al in 2006, group 1 
received nifedipine 10mg tablet orally and repeated every 20 minutes 
(maximum dose of 40mg in the first hour). If contractions subsided, then the 
nifedipine maintenance dose would be 10 - 20mg 6th hrly. Group 2 received 
magnesium sulphate, loading dose of 4 grams iv over 15 minutes, then a 
maintenance dose of 2-3g/hr as iv infusion. In our study both the drugs were 
used at a much lower dose; with 48.4% of patients requiring 16 grams of 
MgSo4 and 48.2% of patients requiring 20mg of nifedipine to stop contractions 
among the success group. 
Tsatsaris et al in 200l, has concluded that nifedipine was more effective 
in delaying delivery for atleast 48 hours and was more likely to prolong 
pregnancy beyond 34 weeks when compared with any other tocolytics. 
Mild and severe maternal and neonatal adverse effects were more 
frequent with MgSo4 (Larmon JE et al). In a study conducted by Sakhavar et 
al (2008), the most common side effect of MgSo4 was hyperthermia (53.4%) 
and most of the patients in this group experienced some kind of adverse effects. 
In a study conducted by Ferguson et al (1990), nifedipine caused headache in 
5-6% and palpitations in 0-6% of patients. In our study, the commonest side 
effects were flushing (21%) and headache (14%) in group A and group B 
respectively. 
 Nifedipine has been reported to reduce neonatal morbidity (RDS & 
IVH) compared to other tocolytics (Papatonis et al, 2000). 
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Nifedipine has an excellent safety profile. Oral nifedipine could be a 
suitable and more convenient alternative to intravenous magnesium sulphate in 
arresting preterm labour. Magnesium sulphate is not as effective as nifedipine 
and is unpleasant for women. 
  
 
 
 
SUMMARY 
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SUMMARY 
 
 
In this prospective randomised controlled trial of comparison of safety 
and efficacy of intravenous magnesium sulphate and oral nifedipine it was 
observed that: 
1. Preterm labour was common in the age group of 20-24 years in both the 
groups . 
2. Preterm labour occurred with a higher frequency in primigravida, 
belonging to class V socioeconomic status with inappropriate antenatal 
care. 
3. Between 31-32 weeks of pregnancy there were 35% of patients in group 
A and 29% of patients in group B. Between 33-34 weeks there were 
39% of patients in group A and 42% in group B. 
4. Previous history of preterm delivery was present in 9% of patients in 
group A and 8% in group B. History of second trimester abortion was 
present in 6% of patients in group A and 4% in group B. 
5. In group A, the commonest side effect was flushing which occurred in 
21% of patients. 
In group B, the commonest side effect was headache which was 
observed in 14% of patients. 
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On an average, patients with side effects were 52% in group A 
and 35% in group B. In both the study groups there was no maternal 
mortality. 
6. Cephalic presentation was found in 85% of patients in group A and 87% 
in group B. Others had breech presentation with a small percentage of 
patients in transverse lie. 
7. When the cervix was 25% effaced, prolongation of pregnancy beyond 
48 hours was observed in 86.2% of patients in group A and 100% in 
group B. With 50% cervical effacement, successful tocolysis was 
observed in 60.7% of patients in group A and 85.7% in group B. With 
75% cervical effacement, successful tocolytic effect was seen in 20% of 
patients in group A and 52.2% in group B. 
8. When the cervix was 1cm dilated, successful tocolysis was observed in 
79.5% of patients in group A and 97.3% in group B. With 2cm cervical 
dilatation, prolongation of pregnancy beyond 48hours was observed in 
52% and 76% of patients in group A and B respectively. When the 
cervix was 3cm dilated, none of the patients in group A had 
prolongation of pregnancy beyond 48 hours and 66.7% of patients in 
group B had successful tocolysis. 
9. Success of acute tocolysis defined as delay of delivery for more than 
48hours was observed in 62% of patients in group A compared with 
83% in group B. 
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10.  Duration of prolongation beyond 2 weeks was observed in 3% of 
patients in group A and 6% in group B, and all these patients delivered 
beyond 37weeks of gestation with very good neonatal outcome. 
11.  Between 33-34 weeks of gestation, prolongation of pregnancy beyond 
48 hours was observed in 69.2% of patients in group A and 92.8% of 
patients in group B. In the gestational age group of 28-30 weeks success 
of tocolysis was observed in 50% and 65.5% of patients in group A and 
group B respectively. 
12.  Among patients with successful tocolysis 4g of MgSo4 was required in 
3.22% of patients, 16g in 48.4% and >16g in 35.48% of patients in 
group A. 
In group B, among the success group 20 mg of nifedipine was 
required in 48.2% of patients. 40 mg and 50 mg were required in 44.6% 
and 7.2% of patients respectively. 
13.  98% and 97% of patients delivered vaginally in group A and group B 
respectively. 
14.  76.3% and 88.8% of babies belonging to group A and group B 
respectively had an apgar score of > 7. 
15.  Babies weighing 2-2.5kg were delivered in 53% and 58% of patients in 
group A and group B respectively. Birth weight of >2.5kg was observed 
in 3% of patients in group A and 6% in group B. 
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16.  RDS / apnoea of immaturity, the most frequent complication of 
prematurity was seen in 12% of patients in group A and 6% in group B. 
Septicemia developed in 7% and 3% of patients in group A and group B 
respectively. Intraventricular haemorrhage the most dreaded 
complication developed in 3% of patients in group A and 2% in group B. 
17.  Among the success group neonatal mortality was observed in 8% and 
4.8% of patients in group A and group B respectively. 
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CONCLUSION 
 
Tocolytics do appear to delay delivery long enough for successful 
administration of corticosteroids one of the few interventions of clear benefit. 
 The perfect tocolytic, which is uniformly effective and has no 
fetomaternal side effects doesn’t exist. Currently available data suggest that 
magnesium sulphate administration doesn’t increase the risk of fetal and 
neonatal mortality. Though MgSo4 is effective in preventing preterm labour, 
nifedipine is safe, well tolerated, with few fetomaternal side effects, non 
invasive and more effective with low purchase price (RCOG, 2011). However, 
close monitoring is still recommended to avoid and reduce any associated 
morbidity when these tocolytic agents are used. 
 In our study, nifedipine was more effective and rather safe tocolytic 
agent associated with more rapid arrest of contractions, more frequent 
successful prolongation of pregnancy, better side effect profile, no serious 
maternal adverse reactions, resulting in good neonatal outcome and 
significantly fewer admissions of newborn to the NICU, when compared to 
magnesium sulphate.  
 Using nifedipine simplifies tocolytic administration and decreases 
hospital stay without increasing the risk of prematurity. 
Preterm labour and delivery is the major cause of perinatal morbidity 
and mortality especially in developing countries like India. Preventable and 
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treatable cause of preterm labour should be identified and dealt with for better 
maternal and neonatal outcome. 
 To conclude, the use of nifedipine as the first line tocolytic is safe when 
compared to MgSo4. But severe maternal hypotension can occur and close 
monitoring of vitals is warranted. 
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COMPARISON OF SAFETY AND  EFFICACY OF 
INTRAVENOUS MAGNESIUM SULPHATE AND  
ORAL NIFEDIPINE IN TREATMENT OF PRETERM 
LABOUR 
 
PROFORMA 
 
NAME:     AGE:   I.P. NO.: 
ADDRESS: 
OCCUPATION:    SOCIO ECONOMIC STATUS: 
DATE & TIME OF ADMISSION: 
DATE & TIME OF DELIVERY: 
DATE OF DISCHARGE: 
OBSTETRIC CODE: G P L A D 
LMP:     EDD:    
GESTATIONAL AGE IN WEEKS: 
BOOKED/ UNBOOKED   IMMUNISED/ NOT IMMUNISED 
HISTORY OF PRESENTING ILLNESS: 
o Lower abdominal pain 
o Fetal movements 
o Vaginal discharge 
o Bleeding PV 
o Draining PV 
o Fever 
o UTI/ URI 
o Other infections 
o Coitus 
o Trauma  
 93 
MENSTRUAL HISTORY: 
MARITAL HISTORY: 
OBSTETRIC HISTORY: 
Previous obstetric outcome 
PAST OBSTETRIC HISTORY: 
o H/O Preterm labour 
o H/O Abortion:  Induced/ Spontaneous 
o Stillbirth 
PAST MEDICAL HISTORY 
 Diabetes/ Hypertension/ TB/ Heart Disease/ Jaundice/ Epilepsy/ Renal 
disease/ STD 
PERSONAL HISTORY 
 Smoking /Alcohol 
GENERAL EXAMINATION: 
Febrile   Pallor   Pedal Edema   Icterus 
VITALS: 
Temp:  PR:  BP: RR:  Ht:  Wt: BMI: 
SYSTEMIC EXAMINATION: 
CVS:     RS:     CNS: 
OBSTETRIC EXAMINATION: 
P/A  
 Symphysio fundal height 
 Uterine size in weeks 
 Contractions 
 Presenting part 
 Position 
 Liquor 
 FHR 
 EFW 
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P/V 
• Cervix 
o Effacement 
o Dilatation 
o Consistency 
o Position 
• Station 
• Membrane 
• Pelvis 
• Draining  pv / bleeding  pv 
• Show 
• Bishop’s score 
INVESTIGATIONS 
 Urine: Sugar/Albumin/Microscopy 
 Urine culture & sensitivity: 
 Complete hemogram: 
 Blood grouping & typing: 
 Blood sugar: 
 Blood urea: 
 Serum creatinine: 
 Serum electrolytes: 
 Vaginal swab culture & sensitivity: 
 ECG 
 CTG 
 USG 
 Singleton/ Multiple 
 Cephalic/ Breech 
 Gestational Age 
 AFI 
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 Placenta 
 Congenital anomalies 
 EFW 
GROUP A     GROUP B 
INTRAVENOUS MgSO4    ORAL NIFEDIPINE 
4g bolus followed by 1g/hr infusion 20mg stat followed by 20mg after  
      30minutes if contractions persist,  
then 10mg 8th hrly  
 
PERIOD OF TOCOLYSIS:   
SIDE EFFECTS: 
GROUP A     
 Flushing 
 Nausea/vomiting 
 Headache 
 Drowsiness  
 Muscle weakness 
 Pulmonary edema 
 Respiratory depression 
 Neonatal complication 
TIME DOSE CONTRACTION PR (b/min) 
BP 
(mm Hg) 
RR 
(breaths/
min) 
KNEE 
JERK 
URINE 
OUTPUT FHR 
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GROUP B 
 Dizziness 
 Palpitations/ tachycardia 
 Transient hypotension 
 Headache 
 Flushing 
 Nausea 
 Peripheral edema 
 Fetal hypoxia 
FETAL OUTCOME: 
 Mode of delivery: 
 GA at delivery: 
 Alive/ Stillborn: 
 Sex: 
 Birth Weight: 
 APGAR: 1’  
 5’ 
 Treatment- Delivery interval: 
 Neonatal complications:  Admitted/ Not admitted 
o Hypothermia 
o  RDS/Apnoea of immaturity 
o Sepsis 
o Feeding problems 
o Hyperbilirubinemia 
 Neonatal death: 
 YES / NO 
 CAUSE: 
  
 
 
 
MASTER CHART 
S. No. Name Age IP No. SES DOA 
Obstetric 
Code 
Booking 
Status 
GA at 
Admn 
(weeks) 
H/O PTL 
H/O 2nd 
TA 
Group 
Maternal 
S/E 
Presentation 
Cx 
Effacement 
% 
Cx 
dilatation 
(cm) 
Station 
GA at 
Del(weeks) 
TDI 
(days) 
Birth Wt. 
(kg) 
Apgar 
Neonatal 
outcome 
1. Saraswathi 24 31781 IV 5.7.11 G2 UB 32 - - A - C 50 2 -1 32+2 2 2.1 7  
2. Periyakka 18 31946 V 6.7.11 P B 29 - - A N/V C 25 1 -3 29+3 3 1.1 4 I 
3. Thamaraiselvi 21 32516 V 9.7.11 G2 UB 30 - + B - C 75 2 -1 30 6 hrs 1.5 4  
4. Saranya 27 32924 III 9.7.11 P UB 28 - - A - B 50 2 -2 28 1 day 1.05 4 II, VI, VII 
5. Rani 20 33498 V 12.7.11 P B 30 - - A F C 25 1 -1 30+4 4 1.2 3  
6. Kiruthika 22 33961 V 15.7.11 P UB 32 - - A - C 50 2 -3 32 10 hrs 2.2 4 V, IV 
7. Pichaimani 22 34403 V 15.7.11 P UB 29 - - B  C 50 2 -3 29+2 2 1.2 3 I 
8. Devika 19 34772 III 21.7.11 P B 33 - + A Dr C 25 2 -3 33 12 hrs 2.2 6 V 
9. Ranjini 27 34792 III 26.7.11 G3 B 34 - - B - C 75 2 -1 34 4 hrs 2.2 8  
10. Parveen Begum 26 35047 V 31.7.11 P B 33 - - B  B 75 3 0 33 6 hrs 2.3 8 IV, V 
11. Nagarani 29 35665 III 1.8.11 P B 32 - - A - C 25 1 -2 32+2 2 1.8 8  
12. Dhanalakshmi 23 35676 IV 6.8.11 P UB 32 - - B H C 25 1 -2 33+2 9 2.1 6  
13. Vasanthi 24 36105 V 6.8.11 G2 UB 28 - - A - C 50 1 -3 29 7 1 kg 5 II, VII 
14. Bahadur Nisha 20 36282 V 11.8.11 G2 UB 28 - - A N/V C 50 2 -1 29+3 10 1.1 4 II 
15. Jeyanthi 25 36299 IV 16.8.11 P B 30 - - A - C 25 1 -2 31+2 9 1.2 6 V, III 
16. Sathya 23 36316 V 18.8.11 P UB 31 - - B Di C 50 2 -3 31 18 hrs 2 4 VII, III 
17. Nadiya 28 36420 V 18.8.11 P UB 33 - - B - C 25 1 -2 34+4 11 2.3 8  
18. Jeevitha 30 36962 V 22.8.11 G3 B 30 - - B - C 25 1 -3 31+2 9 1.5 5  
19. Bhanupriya 32 37086 IV 24.8.11 G2 B 32 - - A - C 50 1 -1 32 20 hrs 1.8 4 I, V 
20. Punitha 23 37595 V 29.8.11 P UB 32 - - B - C 75 2 0 32 6 hrs 2.1 6 I 
21. Anjalai 19 37684 V 29.8.11 P UB 33 - - A - C 50 2 -3 33 12 hrs 2.2 7 IV 
22. Bhuvana 20 38450 V 12.9.11 P UB 34 - - B H C 25 1 -3 37 21 2.6 9  
23. Priya 27 38752 IV 15.9.11 P UB 30 - - A - C 50 2 -3 30 22 hrs 1.3 4 I, IV 
24. Priyadharshini 26 38799 V 19.9.11 G3 B 30 - - B - C 50 2 -3 30 12 hrs 1.3 6 VII, II 
25. Jeyakodi 24 38826 V 19.9.11 P B 31 - - B Di C 25 1 -3 32+5 12 1.8 6  
26. Krishnammal 25 39120 III 22.9.11 G2 UB 29 - - A - B 50 2 -2 29 15 hrs 1.2 3 I, VII, II 
27. Vasanthi 21 39374 IV 23.9.11 P B 32 - - A - C 50 1 -2 32+3 3 2.1 5 V 
28. Mariyammal 24 39382 V 25.9.11 G2 B 33 - - B - C 25 2 -2 33+3 3 2.3 8  
29. Abhirami 23 39778 IV 30.9.11 P UB 28 - - B - C 50 2 -3 28+3 3 1.1 3 VII, III 
30. Premalatha 23 39793 V 30.9.11 G3 UB 30 - - B  BP C 75 3 -1 30 4 hrs 1.4 4 II, VII 
31. Indhra 22 39769 III 31.9.11 P B 33 - - A - C 25 2 -3 33+2 2 2.2 8 IV 
32. Kavitha 31 39840 IV 1.10.11 G2 B 32 + - A H,F C 75 3 0 32 18 hrs 2.2 6 IV 
33. Sasikala 30 39900 V 6.10.11 P UB 34 - - A - B 50 1 -2 34 15 hrs 2.4 8  
34. Usha 19 40290 V 8.10.11 P UB 31 - - B P C 50 2 -2 31+3 3 1.6 6 V 
35. Selvam 24 40464 IV 8.10.11 P UB 32 - - 4 - C 50 2 -1 33 7 2.3 8  
36. Akila 20 40955 V 18.10.11 P UB 33 - - B - C 25 2 -3 33+5 5 2.4 8 I 
37. Rasathi 24 41289 V 20.10.11 P B 31 - - B - C 50 2 -1 31+3 3 1.6 8  
38. Sampoornam 33 41559 V 25.10.11 G2 UB 34 + - B H C 75 2 -1 34 6 hrs 2.4 8 II, V 
39. Chinnaponnu 25 41658 III 12.11.11 G2 B 32 - - A F C 25 1 -3 32+3 3 2.2 6 IV, I 
40. Sudha 27 41748 V 14.11.11 G2 UB 32 - + A N/V, F C 50 2 -3 32 12 hrs 2.3 3  
41. Amirtham 30 42317 V 14.11.11 P UB 33 - - B P TL 25 2 -2 33+3 3 2.1 8 V 
42. Suseela 26 42357 V 19.11.11 P UB 33 - - A F, Dr C 50 1 -2 33 1 day 2.3 8 V 
43. Malathi 28 42368 IV 20.11.11 P B 28 - - B Di C 50 2 -3 28 16 hrs 1.2 3 VII, VI 
44. Bakkiyam 22 42251 V 24.11.11 P UB 31 - - A N/V C 50 2 -2 31 10 hrs 2 5 VII, II 
45. Sangeetha 21 42359 III 24.11.11 P B 30 - - B - C 25 1 -3 31+6 13 1.2 5  
46. Kalamani 23 42446 V 24.11.11 G2 B 32 - - A H, F C 50 2 -3 33+1 8 2.2 6 I, V 
47. Nithya 21 42897 IV 26.11.11 P B 34 - - B Di C 75 3 0 34+2 2 2.2 8  
48. Suryadevi 19 43011 V 28.11.11 P B 33 - - A - C 50 2 -1 33+2 2 2.4 8 IV 
49. Vijayalakshmi 26 43020 V 29.11.11 G4 UB 34 + - B - C 50 2 -3 34+3 3 2.3 8  
50. Menaka 25 43077 V 29.11.11 G3 UB 33 - - A - C 75 2 -3 33 6 hrs 2.4 7  
51. Nandinidevi 25 43086 IV 3.12.11 P UB 34 - - B  BP C 50 2 -2 34+3 3 2.3 8  
52. Rani 28 43208 V 4.12.11 G3 B 34 - - A - C 25 1 -2 34+3 3 2.5 8  
53. Parveen 22 43234 V 4.12.11 G2 UB 31 - - B - C 50 2 -2 31+6 6 1.6 6 II, I 
54. Anandi 37 43239 V 5.2.11 G2 UB 31 - - B - C 25 2 -3 31+4 4 1.5 7  
55. Radhika 29 43410 IV 7.12.11 P UB 30 - - A - C 50 1 -2 30+3 3 1.4 4 VII, VI, IV 
56. Valli 30 43707 V 7.12.11 G2 UB 34 - - B N/V C 25 1 -2 37 21 2.7 9  
57. Devi 21 43753 V 10.12.11 P B 33 - - B - C 50 1 -3 33+3 3 2.4 8  
58. Shanthi 23 43852 IV 12.12.11 G2 UB 29 - - B - B 25 1 -2 30+4 11 1.1 4 VII, II 
59. Nandini 25 44011 V 12.12.11 P UB 34 - - A Dr C 50 2 -3 34 15 hrs 2.5 8 I, V 
60. Sharadha 27 44021 V 15.12.11 G3 B 32 - - B H C 50 2 -3 32 15 hrs 2.3 6  
61. Indrani 27 44311 III 17.12.11 G2 B 33 - - B - C 25 2 -2 33+3 3 2.4 8  
62. Sulochana 23 44536 V 17.12.11 G2 B 32 + - A - C 50 1 -2 32 1 day 2.4 4 IV, V 
63. Padmavathi 22 44625 V 20.12.11 P B 31 - - B Di C 75 2 -1 31 4 hrs 2 5  
64. Mookayee 27 44713 V 21.12.11 P UB 30 - - A F C 50 1 -2 30+2 2 1.3 3 I, VI, VII 
65. Palaniyammal 20 44758 V 22.12.11 P UB 28 - - B - C 75 3 -3 28 4 hrs 1 kg 3 III, VII 
66. Deepa 20 44895 III 24.12.11 P UB 33 - - A - B 50 1 -3 33+5 5 2.4 8 V, IV 
67. Ramya 18 45861 IV 24.12.11 P UB 30 - - B F C 50 2 -2 30 6 hrs 1.2 4 VII, VI 
68. Kokila 30 45883 III 26.12.11 P B 34 - - A - C 25 1 -1 35 7 2.4 8  
69. Alagammal 28 45903 IV 28.12.11 G3 UB 29 - + B - C 25 1 -3 30+2 9 1.1 3  
70. Gayathri 31 45982 V 28.12.11 P B 30 - - A - B 75 3 -2 30 6 hrs 1.4 3 III, VII 
71. Juliet 24 45999 IV 29.12.11 G3 B 34 - - B - C 75 2 -2 34+2 2 2.2 8  
72. Kavitha 24 46214 V 29.12.11 P UB 34 - - A - C 75 2 -2 34 12 hrs 2.5 7  
73. Noorjahan 21 46350 V 31.12.11 P UB 32 - - A H C 50 2 -3 32 15 hrs 2.2 4 III, VII 
74. Malarmani 24 32 IV 1.1.12 P B 28 - - B - C 50 2 -3 28+3 3 1.1 4 VII, V 
75. Sendamarai 20 49 V 1.1.12 P B 30 - - A N/V B 25 1 -3 30+3 3 1.3 3 II, VII 
76. Ilakkiya 26 129 III 2.1.12 P UB 32 - - B H C 50 1 -3 32+4 4 2.1 8  
77. Vimalarani 28 248 IV 4.1.12 G2 UB 34 + - A - C 50 1 -3 34+2 2 2.4 8  
78. Amirthavalli 27 540 V 6.1.12 G3 UB 33 - - B N/V C 25 2 -2 33+6 6 2.1 8 IV, V 
79. Sudha 22 592 V 6.1.12 P B 30 - - A - C 50 2 -3 30 18 hrs 1.2 3 I, IV, V 
80. Palaniyammal 23 702 III 7.1.12 G2 B 34 - - B Di C 75 2 -2 34+3 3 2.2 8  
81. Mariyayee 20 1096 V 10.1.12 P UB 31 - - A F C 50 1 -3 31+6 6 1.4 5 V 
82. Eshwari 25 1131 IV 11.1.12 G2 UB 32 - - B - B 75 2 -1 32 6 hrs 2 7  
83. Reshma 30 1236 V 11.1.12 G4 UB 33 - + A F, N/V C 50 1 -2 33+3 3 2.4 8 IV, V 
84. Maheswari 19 1323 IV 12.1.12 P B 32 - - B P C 50 1 -3 32+4 4 2.1 8  
85. Kamalam 31 1628 V 15.1.12 G4 UB 34 + - A F C 25 2 -3 37+1 22 2.7 8 I, V 
86. Annakamu 30 1720 III 16.1.12 G4 B 29 - - B - C 25 1 -3 29+5 5 1.2 4  
87. Pushpam 21 1730 V 16.1.12 P B 30 - - A - C 25 1 -2 30+4 4 1.5 4 I 
88. Megala 24 1799 IV 19.1.12 P UB 31 - - A - C 50 1 -2 31+6 6 1.7 6  
89. Sivaranjini 36 1963 V 22.1.12 P UB 33 - - B N/V C 25 2 -3 33+3 3 2.2 8 I 
90. Umarani 22 1986 V 23.1.12 G2 B 34 - - A F B 50 2 -3 34+3 3 2.4 8  
91. Kalaiselvi 20 2484 III 23.1.12 G2 B 32 + - B - C 50 1 -3 32+4 4 2 8 I 
92. Latha 23 2496 IV 26.1.12 P B 33 - - A - C 75 2 -2 33+2 2 1.9 8  
93. Sumathi 25 2566 V 27.1.12 G3 UB 29 - - B P C 50 1 -2 29+6 6 1.1 5 VII, II 
94. Reena 28 3303 III 27.1.12 G4 UB 32 - - A - C 50 2 0 33 7 2.2 8 IV 
95. Nagalakshmi 18 3365 IV 28.1.12 G2 UB 31 + - A F, PE C 25 1 -1 31 1 day 1.8 4 II, VII 
96. Annalakshmi 22 3399 V 29.1.12 P UB 30 - - B - B 50 3 -3 30+3 3 1.3 6  
97. Mariyapriya 23 3437 V 29.1.12 P B 34 - - B - C 75 3 -1 34+2 2 2.1 8 IV 
98. Manjula 21 3749 V 29.1.12 P UB 34 - - A H C 50 2 -2 34 15 hrs 2.4 8 V 
99. Meena 25 4100 V 2.2.12 P B 33 - - B - C 25 1 -2 34+1 8 2.2 8  
100. Kaveri 28 4123 IV 4.2.12 G3 UB 32 - - A - TL 50 2 -3 32 10 hrs 1.9 6  
101. Divya 28 4213 V 5.2.12 G2 B 34 - + B - C 25 2 -3 34+5 5 2.3 8  
102. Chandra 21 4300 V 10.2.12 G2 UB 29 - - A - C 50 1 -2 29 12 hrs 1.2 3 III, VII 
103. Padma 27 4359 V 10.2.12 G4 UB 28 - - B - C 25 1 -3 28+4 4 1.2 6  
104. Subbulakshmi 29 4400 V 11.2.12 P B 31 - - B - C 25 2 -3 31+3 3 2 8 I 
105. Vanitha 21 4452 V 15.2.12 P UB 33 - - A - B 50 2 -3 33+3 3 2.2 8 I 
106. Neelamani 30 4808 V 17.2.12 P UB 33 - - B - C 50 1 -3 33+6 6 2.1 8  
107. Mumtaj 32 4829 V 20.2.12 P B 32 - - A Dr C 75 2 -2 32 6 hrs 1.8 4 IV 
108. Nagarathinam 28 4965 IV 20.2.12 G2 B 34 + - A N/V C 50 2 -1 34+2 2 2.5 8 I 
109. Muthulakshmi 26 5273 IV 25.2.12 P UB 30 - - B H C 50 1 -2 30+5 5 1.1 8 IV 
110. Flora 24 5299 III 28.2.12 G2 UB 34 - - A - C 75 3 -2 34 4 hrs 2.5 8  
111. Yashodha 28 5371 V 1.3.12 G2 UB 34 - - B - C 50 2 -2 34+4 4 2.3 8 IV 
112. Chitra 27 5420 III 1.3.12 P B 28 - - A - C 75 2 -1 2.8 4 hrs 1.2 3 II, VII 
113. Rajeshwari 20 6434 IV 2.3.12 P B 31 - - B Di C 50 2 -1 31+3 3 1.5 7  
114. Renukadevi 23 6512 V 4.3.12 G3 B 30 - + B - B 25 1 -3 31+2 9 1.4 6  
115. Jyothi 21 6591 V 4.3.12 P UB 31 - - A F C 25 1 -3 32 7 1.7 6 IV, V 
116. Poornima 26 6926 IV 4.3.12 G3 UB 32 + - A - C 25 1 -3 33+3 10 1.9 8  
117. Geetha 22 7537 V 6.3.12 P B 30 - - B P C 75 2 -2 30 4 hrs 1.3 4 VII, V 
118. Manohari 34 7547 V 6.3.12 G2 B 34 - - A - C 50 1 -2 34+2 2 2.3 8 IV, V 
119. Sukanya 18 7639 V 7.3.12 P UB 33 - - B H C 50 1 -3 33+6 6 2.2 8 I 
120. Alamelu 22 7789 V 8.3.12 P UB 34 - - A - C 50 2 -1 35+5 12 2.4 8  
121. Thangammal 27 7812 V 10.3.12 G4 UB 32 - - B - C 25 1 -3 33 7 2.1 8  
122. Revathi 29 8029 V 10.3.12 G2 B 30 - - A - B 50 2 -1 30 12 hrs 1.2 4 VII, II 
123. Kanaka 22 8106 V 11.3.12 P UB 32 - - B - C 25 1 -3 32+5 5 2.1 8  
124. Poovathi 28 8255 IV 13.3.12 G2 B 33 + - A - C 50 1 -2 33+4 4 2.3 6  
125. Tharanika 27 8273 III 13.3.12 P UB 31 - - B - C 50 1 -2 31+4 4 2 8 V 
126. Mariyayee 23 8280 V 15.3.12 G2 B 33 - - A H C 25 2 -3 33+3 3 1.6 8  
127. Shakunthala 21 8285 III 17.3.12 P B 31 - - A - C 25 2 -1 32 7 1.5 5  
128. Shivagami 20 8569 III 18.3.12 G2 UB 34 - - B - C 50 2 -3 35 7 2.2 8 V, IV 
129. Amudha 21 8593 V 18.3.12 P B 32 - - A - C 25 1 -2 33+2 9 2.1 6 IV, V 
130. Vaidehi 23 8776 V 19.3.12 P UB 34 - - B H C 75 2 -1 34+2 2 2.2 8  
131. Vijaya 25 8809 V 20.3.12 P UB 34 - - A F, Dr C 50 1 -1 37+2 23 2.6 8  
132. Sheela 21 8969 V 24.3.12 P B 34 - - B - C 50 2 -3 34+3 3 2.3 8 V 
133. Renganayaki 27 8983 V 24.3.12 G2 UB 30 - - B - B 75 3 -2 30 6 hrs 1.1 3  
134. Divya Bharathi 19 9440 V 27.3.12 P UB 32 - - A - C 50 2 -2 32 12 hrs 2.2 6 III, VII 
135. Jerina Parveen 33 9477 V 29.3.12 P B 30 - - B - C 75 2 -3 30 4 hrs 1.2 4 VII 
136. Ilaiyarasi 35 9503 V 29.3.12 G3 B 31 - - B - C 50 2 -3 31+3 3 1.3 8  
137. Gomathi 26 9508 IV 31.3.12 P UB 29 - - A H C 25 1 -3 30 7 1.2 4 II, VII 
138. Lakshmi 28 9617 IV 3.4.12 G3 B 32 + - B N/V C 75 2 -2 32+2 2 2.1 8 V, IV 
139. Yuvarani 30 9820 V 3.4.12 P UB 33 - - A - C 25 1 -2 33+5 5 2.2 8  
140. Uma 25 10145 V 4.4.12 G2 B 34 - - B - C 50 2 -3 34+2 2 2.2 8  
141. Sheela Devi 26 10185 V 5.4.12 G2 B 31 - - A - C 50 2 -2 31+3 3 1.7 8  
142. Aruna 25 10196 IV 7.4.12 G2 UB 34 - - B H C 25 1 -3 35+3 10 2.4 8  
143. Amudha 25 10525 V 7.4.12 P B 33 - - A - B 50 1 -2 33 15 hrs 1.9 7  
144. Kalpana 22 10591 V 9.4.12 P UB 33 - - B - C 25 2 -3 34+1 8 2.2 8 V 
145. Panchavarnam 21 10620 IV 12.4.12 P UB 32 - - A H C 50 2 -1 32 18 hrs 2.2 6 IV 
146. Kalaiyarasi 19 10663 IV 12.4.12 P B 33 - - A Dr C 50 1 -3 33+6 6 2.3 8  
147. Chandradevi 28 10773 V 12.4.12 P UB 31 - - B Di C 25 1 -3 31+6 6 1.8 8 IV 
148. Bhagyalakshmi 22 10790 V 14.4.12 P B 31 - - A F C 50 2 -1 31+5 5 1.6 6 IV, V 
149. Arpudam 36 10830 IV 16.4.12 P B 30 - - B - B 25 1 -3 30+6 6 1.3 8 IV, V 
150. Chinnaponnu 26 10883 V 16.4.12 G2 UB 32 - + A N/V C 50 2 -3 32+2 2 1.7 8  
151. Pappathi 23 10964 III 17.4.12 G3 UB 29 + - B H C 25 1 -3 30 7 1.2 5 IV, V 
152. Veeramani 28 10991 V 19.4.12 P B 28 - - B - C 75 2 0 28+3 3 1.2 5  
153. Praveena 23 11590 V 20.4.12 P UB 34 - - A - C 25 1 -2 37+3 24 2.3 8  
154. Kamakshmi 21 11596 V 20.4.12 G2 B 32 - - B P C 75 2 -1 32+2 2 2.1 8  
155. Prabhadevi 27 11664 V 23.4.12 G2 UB 28 + - A - C 25 1 -1 28 1 day 1.1 3 I, III, VII 
156. Roja 33 11693 V 23.4.12 G3 UB 33 - + A - C 50 1 -3 33+4 4 2.3 8  
157. Sasikala 22 11790 III 25.4.12 P UB 30 - - B H B 50 2 -1 31 7 1.2 6 IV 
158. Kala 24 12097 IV 25.4.12 P B 34 - - B - C 75 2 -1 34+2 2 2.5 8  
159. Vijaya 21 12547 V 26.4.12 P UB 33 - - A - C 50 1 -2 33+5 5 2.2 8  
160. Asha 24 12593 V 26.4.12 G3 UB 32 + - B - C 50 2 -1 32+6 6 2.2 8 V 
161. Anitha 23 12651 V 27.4.12 G2 B 32 - - A Dr, F C 25 2 -3 32+3 3 2.2 8  
162. Parveen 21 12711 IV 28.4.12 P B 31 - - B - B 50 1 -2 31+5 5 2 8 IV 
163. Yogarani 21 13776 IV 28.4.12 P UB 30 - - A - C 50 2 -3 30 12 hrs 1.4 3 II, VII 
164. Rukmani 27 15776 V 29.4.12 P UB 32 - - B - C 75 3 -2 32+2 2 2.5 8  
165. Jeyamani 28 16876 III 30.4.12 G2 B 34 - - A - TL 25 2 -2 34+3 3 2.2 8  
166. Lalitha 33 16942 V 30.4.12 G2 UB 33 - - A H, Dr C 50 1 -1 34+1 8 1.6 8 V 
167. Allirani 30 16998 IV 31.4.12 P B 33 - - B - C 25 1 -3 33+4 4 2.4 8  
168. Kathun Beevi 19 17258 V 31.4.12 P B 34 - - B - C 50 2 -2 34+4 4 2.5 8  
169. Elanjiyam 24 17741 V 1.5.12 P UB 30 - - A F B 25 2 -2 31+6 13 1.3 5 IV 
170. Arukkani 22 17846 III 2.5.12 G2 UB 28 - - B P C 50 2 -2 29+6 13 1 kg 6 IV, V 
171. Vembu 20 18241 V 2.5.12 P UB 31 - - A - C 25 2 -3 32+4 11 2.2 8 IV 
172. Malarkodi 22 18361 V 2.5.12 P B 34 - - B - B 50 2 -1 34+6 6 2.4 8  
173. Sulochana 22 18424 IV 4.5.12 G2 B 33 - - A Dr, F C 50 1 -1 33+4 14 2.1 8  
174. Jeyalakshmi 25 18444 V 4.5.12 P UB 30 - - A - C 25 1 -2 31+5 12 2.1 5 V 
175. Radha 27 18512 V 5.5.12 P B 29 - - B H C 50 1 -2 29+4 4 1.2 6  
176. Eshwari 24 18567 V 6.5.12 P B 33 - - A - C 75 2 0 33 3 hrs 2.3 5  
177. Gowri 26 18742 V 7.5.12 P UB 32 - - B P C 50 2 -2 32+5 5 2.1 8  
178. Gomathi 26 18861 IV 8.5.12 G2 UB 29 - - A H C 75 2 -2 29 6 hrs 1.2 4 II, VII 
179. Stellamary 23 19203 III 8.5.12 G2 UB 33 - - B - C 50 1 -2 33+4 4 2.2 8  
180. Anbumani 22 19381 III 9.5.12 P B 32 - - A Dr, PE C 25 1 -3 32 1 day 2.3 7 V, VII 
181. Chitra 19 19421 IV 10.5.12 G2 B 34 + - B Di C 25 1 -2 37+2 23 2.6 9  
182. Nilofer 31 19549 III 12.5.12 P UB 33 - - A - B 50 2 -1 33+6 6 2.3 8  
183. Thamarai 28 19687 V 12.5.12 G2 UB 30 - + A N/V C 75 2 -2 30+2 2 1.5 6 IV 
184. Maheswari 27 19939 V 15.5.12 G2 UB 34 - - B - C 50 2 -2 34+3 3 2.4 8  
185. Anjalai 28 19982 IV 22.5.12 G3 B 32 - - A - C 75 2 -1 32+2 2 2.1 8  
186. Renuka 26 20006 IV 24.5.12 G2 B 33 - - B - C 75 3 -2 33+3 3 2.3 8 V 
187. Rekha 29 20406 V 24.5.12 P B 34 - - B - C 50 1 -2 37+3 24 2.7 9  
188. Jeyachandra 20 20442 III 25.5.12 P UB 33 - - A - C 50 2 -2 33+5 5 2.1 8  
189. Kamakshi 26 20452 V 26.5.12 P UB 32 - - A - B 50 2 -1 32+3 3 2.2 8 IV 
190. Arul Devi 28 29835 V 30.5.12 G2 B 32 + - B - C 25 2 -2 32+3 3 2 8  
191. Geetha 27 20891 IV 6.6.12 G2 B 34 - - A F C 75 2 -3 34 8 hrs 2.4 8  
192. Lakshmi 30 21372 V 10.6.12 G3 B 34 - - B N/V C 25 1 -2 37+2 23 2.8 9 IV, V 
193. Malathi 23 21447 V 10.6.12 G3 B 31 - - A - C 75 2 -2 31+2 2 1.4 8  
194. Rajeshwari 22 21984 III 12.6.12 P UB 30 - - A Dr C 50 1 -2 30 12 hrs 1.3 3 V, VII 
195. Malar 19 22474 IV 12.6.12 P UB 32 - - B - C 50 2 -2 32+2 2 2 8  
196. Tamilarasi 34 22496 IV 14.6.12 G4 UB 34 - - B H TL 50 1 -1 37+4 25 2.6 8  
197. Selvarani 23 22512 V 22.6.12 P UB 31 - - A - C 25 1 -3 31+3 3 1.2 8  
198. Hemapriya 33 22617 V 24.6.12 P B 29 - - A F C 75 3 -2 29 3 hrs 1.1 3 III, VII 
199. Annalakshmi 21 23011 V 24.6.12 G3 UB 33 - - B - C 25 1 -2 33+4 4 2.1 8  
200. Muthuselvi 36 23311 IV 27.6.12 G4 UB 30 - - B - B 25 2 -2 30+5 5 1.5 6  
 
ABBREVIATIONS 
 
SES  - Socioeconomic Status 
DOA  - Date of Admission 
GA at Admn- Gestational Age at Admission 
H/O 2nd TA - History of Second Trimester Abortion 
H/O PTL - History of Preterm Labour 
Mat S/E - Maternal Side Effects 
GA at Del - Gestational Age at Delivery 
TDI  - Treatment Delivery Interval 
B. Wt  - Birth Weight 
UB  - Unbooked 
B  - Booked 
F - Flushing 
H  - Headache 
N/V  - Nausea / Vomiting 
Dr  - Drowsiness 
PE  - Pulmonary Edema 
Di  - Dizziness 
P  - Palpitations 
↓ BP  - Hypotension 
C  - Cephalic 
B  - Breech 
Tr  - Transverse Lie 
I  - Hypothermia 
II  - Respiratory Distress Syndrome / Apnoea of Immaturity 
III  - Sepsis 
IV  - Feeding Problems 
V  - Hyperbilirubinemia 
VI  - Intraventricular Haemorrhage 
VII  - Neonatal Death 
 
 
